

# An open-source framework for end-to-end analysis of electronic health record data

Received: 11 December 2023

Accepted: 25 July 2024

Published online: 12 September 2024



A list of authors and their affiliations appears at the end of the paper

With progressive digitalization of healthcare systems worldwide, large-scale collection of electronic health records (EHRs) has become commonplace. However, an extensible framework for comprehensive exploratory analysis that accounts for data heterogeneity is missing. Here we introduce ehrapy, a modular open-source Python framework designed for exploratory analysis of heterogeneous epidemiology and EHR data. ehrapy incorporates a series of analytical steps, from data extraction and quality control to the generation of low-dimensional representations. Complemented by rich statistical modules, ehrapy facilitates associating patients with disease states, differential comparison between patient clusters, survival analysis, trajectory inference, causal inference and more. Leveraging ontologies, ehrapy further enables data sharing and training EHR deep learning models, paving the way for foundational models in biomedical research. We demonstrate ehrapy's features in six distinct examples. We applied ehrapy to stratify patients affected by unspecified pneumonia into finer-grained phenotypes. Furthermore, we reveal biomarkers for significant differences in survival among these groups. Additionally, we quantify medication-class effects of pneumonia medications on length of stay. We further leveraged ehrapy to analyze cardiovascular risks across different data modalities. We reconstructed disease state trajectories in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on imaging data. Finally, we conducted a case study to demonstrate how ehrapy can detect and mitigate biases in EHR data. ehrapy, thus, provides a framework that we envision will standardize analysis pipelines on EHR data and serve as a cornerstone for the community.

Electronic health records (EHRs) are becoming increasingly common due to standardized data collection<sup>1</sup> and digitalization in healthcare institutions. EHRs collected at medical care sites serve as efficient storage and sharing units of health information<sup>2</sup>, enabling the informed treatment of individuals using the patient's complete history<sup>3</sup>. Routinely collected EHR data are approaching genomic-scale size and complexity<sup>4</sup>, posing challenges in extracting information without quantitative analysis methods. The application of such approaches to EHR databases<sup>5–9</sup> has enabled the prediction and classification of diseases<sup>10,11</sup>, study of population health<sup>12</sup>, determination of optimal

treatment policies<sup>13,14</sup>, simulation of clinical trials<sup>15</sup> and stratification of patients<sup>16</sup>.

However, current EHR datasets suffer from serious limitations, such as data collection issues, inconsistencies and lack of data diversity. EHR data collection and sharing problems often arise due to non-standardized formats, with disparate systems using exchange protocols, such as Health Level Seven International (HL7) and Fast Healthcare Interoperability Resources (FHIR)<sup>17</sup>. In addition, EHR data are stored in various on-disk formats, including, but not limited to, relational databases and CSV, XML and JSON formats. These variations

✉ e-mail: [fabian.theis@helmholtz-muenchen.de](mailto:fabian.theis@helmholtz-muenchen.de)

pose challenges with respect to data retrieval, scalability, interoperability and data sharing.

Beyond format variability, inherent biases of the collected data can compromise the validity of findings. Selection bias stemming from non-representative sample composition can lead to skewed inferences about disease prevalence or treatment efficacy<sup>18,19</sup>. Filtering bias arises through inconsistent criteria for data inclusion, obscuring true variable relationships<sup>20</sup>. Surveillance bias exaggerates associations between exposure and outcomes due to differential monitoring frequencies<sup>21</sup>. EHR data are further prone to missing data<sup>22,23</sup>, which can be broadly classified into three categories: missing completely at random (MCAR), where missingness is unrelated to the data; missing at random (MAR), where missingness depends on observed data; and missing not at random (MNAR), where missingness depends on unobserved data<sup>22,23</sup>. Information and coding biases, related to inaccuracies in data recording or coding inconsistencies, respectively, can lead to misclassification and unreliable research conclusions<sup>24,25</sup>. Data may even contradict itself, such as when measurements were reported for deceased patients<sup>26,27</sup>. Technical variation and differing data collection standards lead to distribution differences and inconsistencies in representation and semantics across EHR datasets<sup>28,29</sup>. Attrition and confounding biases, resulting from differential patient dropout rates or unaccounted external variable effects, can significantly skew study outcomes<sup>30–32</sup>. The diversity of EHR data that comprise demographics, laboratory results, vital signs, diagnoses, medications, x-rays, written notes and even omics measurements amplifies all the aforementioned issues.

Addressing these challenges requires rigorous study design, careful data pre-processing and continuous bias evaluation through exploratory data analysis. Several EHR data pre-processing and analysis workflows were previously developed<sup>4,33–37</sup>, but none of them enables the analysis of heterogeneous data, provides in-depth documentation, is available as a software package or allows for exploratory visual analysis. Current EHR analysis pipelines, therefore, differ considerably in their approaches and are often commercial, vendor-specific solutions<sup>38</sup>. This is in contrast to strategies using community standards for the analysis of omics data, such as Bioconductor<sup>39</sup> or scverse<sup>40</sup>. As a result, EHR data frequently remain underexplored and are commonly investigated only for a particular research question<sup>41</sup>. Even in such cases, EHR data are then frequently input into machine learning models with serious data quality issues that greatly impact prediction performance and generalizability<sup>42</sup>.

To address this lack of analysis tooling, we developed the EHR Analysis in Python framework, ehrapy, which enables exploratory analysis of diverse EHR datasets. The ehrapy package is purpose-built to organize, analyze, visualize and statistically compare complex EHR data. ehrapy can be applied to datasets of different data types, sizes, diseases and origins. To demonstrate this versatility, we applied ehrapy to datasets obtained from EHR and population-based studies. Using the Pediatric Intensive Care (PIC) EHR database<sup>43</sup>, we stratified patients diagnosed with ‘unspecified pneumonia’ into distinct clinically relevant groups, extracted clinical indicators of pneumonia through statistical analysis and quantified medication-class effects on length of stay (LOS) with causal inference. Using the UK Biobank<sup>44</sup> (UKB), a population-scale cohort comprising over 500,000 participants from the United Kingdom, we employed ehrapy to explore cardiovascular risk factors using clinical predictors, metabolomics, genomics and retinal imaging-derived features. Additionally, we performed image analysis to project disease progression through fate mapping in patients affected by coronavirus disease 2019 (COVID-19) using chest x-rays. Finally, we demonstrate how exploratory analysis with ehrapy unveils and mitigates biases in over 100,000 visits by patients with diabetes across 130 US hospitals. We provide online links to additional use cases that demonstrate ehrapy’s usage with further datasets, including MIMIC-II (ref. 45), and for various medical conditions, such as patients

subject to indwelling arterial catheter usage. ehrapy is compatible with any EHR dataset that can be transformed into vectors and is accessible as a user-friendly open-source software package hosted at <https://github.com/theislab/ehrapy> and installable from PyPI. It comes with comprehensive documentation, tutorials and further examples, all available at <https://ehrapy.readthedocs.io>.

## Results

### ehrapy: a framework for exploratory EHR data analysis


The foundation of ehrapy is a robust and scalable data storage backend that is combined with a series of pre-processing and analysis modules. In ehrapy, EHR data are organized as a data matrix where observations are individual patient visits (or patients, in the absence of follow-up visits), and variables represent all measured quantities (Methods). These data matrices are stored together with metadata of observations and variables. By leveraging the AnnData (annotated data) data structure that implements this design, ehrapy builds upon established standards and is compatible with analysis and visualization functions provided by the omics scverse<sup>40</sup> ecosystem. Readers are also available in R, Julia and Javascript<sup>46</sup>. We additionally provide a dataset module with more than 20 public loadable EHR datasets in AnnData format to kickstart analysis and development with ehrapy.

For standardized analysis of EHR data, it is crucial that these data are encoded and stored in consistent, reusable formats. Thus, ehrapy requires that input data are organized in structured vectors. Readers for common formats, such as CSV, OMOP<sup>47</sup> or SQL databases, are available in ehrapy. Data loaded into AnnData objects can be mapped against several hierarchical ontologies<sup>48–51</sup> (Methods). Clinical keywords of free text notes can be automatically extracted (Methods).

Powered by scanpy, which scales to millions of observations<sup>52</sup> (Methods and Supplementary Table 1) and the machine learning library scikit-learn<sup>53</sup>, ehrapy provides more than 100 composable analysis functions organized in modules from which custom analysis pipelines can be built. Each function directly interacts with the AnnData object and adds all intermediate results for simple access and reuse of information to it. To facilitate setting up these pipelines, ehrapy guides analysts through a general analysis pipeline (Fig. 1). At any step of an analysis pipeline, community software packages can be integrated without any vendor lock-in. Because ehrapy is built on open standards, it can be purposefully extended to solve new challenges, such as the development of foundational models (Methods).

In the ehrapy analysis pipeline, EHR data are initially inspected for quality issues by analyzing feature distributions that may skew results and by detecting visits and features with high missing rates that ehrapy can then impute (Methods). ehrapy tracks all filtering steps while keeping track of population dynamics to highlight potential selection and filtering biases (Methods). Subsequently, ehrapy’s normalization and encoding functions (Methods) are applied to achieve a uniform numerical representation that facilitates data integration and corrects for dataset shift effects (Methods). Calculated lower-dimensional representations can subsequently be visualized, clustered and annotated to obtain a patient landscape (Methods). Such annotated groups of patients can be used for statistical comparisons to find differences in features among them to ultimately learn markers of patient states.

As analysis goals can differ between users and datasets, the ehrapy analysis pipeline is customizable during the final knowledge inference step. ehrapy provides statistical methods for group comparison and extensive support for survival analysis (Methods), enabling the discovery of biomarkers. Furthermore, ehrapy offers functions for causal inference to go from statistically determined associations to causal relations (Methods). Moreover, patient visits in aggregated EHR data can be regarded as snapshots where individual measurements taken at specific timepoints might not adequately reflect the underlying progression of disease and result from unrelated variation due to, for example, day-to-day differences<sup>54–56</sup>. Therefore, disease progression



**Fig. 1 | Schematic overview of EHR analysis with ehrapy. a,** Heterogeneous health data are first loaded into memory as an AnnData object with patient visits as observational rows and variables as columns. Next, the data can be mapped against ontologies, and key terms are extracted from free text notes. **b,** The EHR data are subject to quality control where low-quality or spurious measurements are removed or imputed. Subsequently, numerical data are normalized, and

categorical data are encoded. Data from different sources with data distribution shifts are integrated, embedded, clustered and annotated in a patient landscape. **c,** Further downstream analyses depend on the question of interest and can include the inference of causal effects and trajectories, survival analysis or patient stratification.

models should rely on analysis of the underlying clinical data, as disease progression in an individual patient may not be monotonous in time. ehrapy allows for the use of advanced trajectory inference methods to overcome sparse measurements<sup>57–59</sup>. We show that this approach can order snapshots to calculate a pseudotime that can adequately reflect the progression of the underlying clinical process. Given a sufficient number of snapshots, ehrapy increases the potential to understand disease progression, which is likely not robustly captured within a single EHR but, rather, across several.

#### ehrapy enables patient stratification in pneumonia cases

To demonstrate ehrapy's capability to analyze heterogeneous datasets from a broad patient set across multiple care units, we applied our exploratory strategy to the PIC<sup>43</sup> database. The PIC database is a single-center database hosting information on children admitted

to critical care units at the Children's Hospital of Zhejiang University School of Medicine in China. It contains 13,499 distinct hospital admissions of 12,881 individual pediatric patients admitted between 2010 and 2018 for whom demographics, diagnoses, doctors' notes, vital signs, laboratory and microbiology tests, medications, fluid balances and more were collected (Extended Data Figs. 1 and 2a and Methods). After missing data imputation and subsequent pre-processing (Extended Data Figs. 2b,c and 3 and Methods), we generated a uniform manifold approximation and projection (UMAP) embedding to visualize variation across all patients using ehrapy (Fig. 2a). This visualization of the low-dimensional patient manifold shows the heterogeneity of the collected data in the PIC database, with malformations, perinatal and respiratory being the most abundant International Classification of Diseases (ICD) chapters (Fig. 2b). The most common respiratory disease categories (Fig. 2c) were labeled pneumonia and influenza



( $n = 984$ ). We focused on pneumonia to apply ehrapy to a challenging, broad-spectrum disease that affects all age groups. Pneumonia is a prevalent respiratory infection that poses a substantial burden on public health<sup>60</sup> and is characterized by inflammation of the alveoli and distal airways<sup>60</sup>. Individuals with pre-existing chronic conditions are particularly vulnerable, as are children under the age of 5 (ref. 61). Pneumonia can be caused by a range of microorganisms, encompassing bacteria, respiratory viruses and fungi.

We selected the age group ‘youths’ (13 months to 18 years of age) for further analysis, addressing a total of 265 patients who dominated the pneumonia cases and were diagnosed with ‘unspecified pneumonia’ (Fig. 2d and Extended Data Fig. 4). Neonates (0–28 d old) and infants (29 d to 12 months old) were excluded from the analysis as the disease context is significantly different in these age groups due to distinct anatomical and physical conditions. Patients were 61% male, had a total of 277 admissions, had a mean age at admission of 54 months (median, 38 months) and had an average LOS of 15 d (median, 7 d). Of these, 152 patients were admitted to the pediatric intensive care unit (PICU), 118 to the general ICU (GICU), four to the surgical ICU (SICU) and three to the cardiac ICU (CICU). Laboratory measurements typically had 12–14% missing data, except for serum procalcitonin (PCT), a marker for bacterial infections, with 24.5% missing, and C-reactive protein (CRP), a marker of inflammation, with 16.8% missing. Measurements assigned as ‘vital signs’ contained between 44% and 54% missing values. Stratifying patients with unspecified pneumonia further enables a more nuanced understanding of the disease, potentially facilitating tailored approaches to treatment.

To deepen clinical phenotyping for the disease group ‘unspecified pneumonia’, we calculated a  $k$ -nearest neighbor graph to cluster patients into groups and visualize these in UMAP space (Methods). Leiden clustering<sup>62</sup> identified four patient groupings with distinct clinical features that we annotated (Fig. 2e). To identify the laboratory values, medications and pathogens that were most characteristic for these four groups (Fig. 2f), we applied  $t$ -tests for numerical data and  $g$ -tests for categorical data between the identified groups using ehrapy (Extended Data Fig. 5 and Methods). Based on this analysis, we identified patient groups with ‘sepsis-like’, ‘severe pneumonia with co-infection’, ‘viral pneumonia’ and ‘mild pneumonia’ phenotypes. The ‘sepsis-like’ group of patients ( $n = 28$ ) was characterized by rapid disease progression as exemplified by an increased number of deaths (adjusted  $P \leq 5.04 \times 10^{-3}$ , 43% ( $n = 28$ ), 95% confidence interval (CI): 23%, 62%); indication of multiple organ failure, such as elevated creatinine (adjusted  $P \leq 0.01$ ,  $52.74 \pm 23.71 \mu\text{mol L}^{-1}$ ) or reduced albumin levels (adjusted  $P \leq 2.89 \times 10^{-4}$ ,  $33.40 \pm 6.78 \text{ g L}^{-1}$ ); and increased expression levels and peaks of inflammation markers, including PCT (adjusted  $P \leq 3.01 \times 10^{-2}$ ,  $1.42 \pm 2.03 \text{ ng ml}^{-1}$ ), whole blood cell count, neutrophils, lymphocytes, monocytes and lower platelet counts (adjusted  $P \leq 6.3 \times 10^{-2}$ ,  $159.30 \pm 142.00 \times 10^9$  per liter) and changes in electrolyte levels—that is, lower potassium levels (adjusted  $P \leq 0.09 \times 10^{-2}$ ,  $3.14 \pm 0.54 \text{ mmol L}^{-1}$ ). Patients whom we associated with the term ‘severe pneumonia with co-infection’ ( $n = 74$ ) were characterized by prolonged ICU stays (adjusted  $P \leq 3.59 \times 10^{-4}$ ,  $15.01 \pm 29.24$  d); organ affection, such as higher levels of creatinine (adjusted  $P \leq 1.10 \times 10^{-4}$ ,  $52.74 \pm 23.71 \mu\text{mol L}^{-1}$ ) and lower platelet count (adjusted  $P \leq 5.40 \times 10^{-23}$ ,  $159.30 \pm 142.00 \times 10^9$  per liter); increased inflammation markers, such as peaks of PCT (adjusted  $P \leq 5.06 \times 10^{-5}$ ,  $1.42 \pm 2.03 \text{ ng ml}^{-1}$ ), CRP (adjusted  $P \leq 1.40 \times 10^{-6}$ ,  $50.60 \pm 37.58 \text{ mg L}^{-1}$ ) and neutrophils (adjusted  $P \leq 8.51 \times 10^{-6}$ ,  $13.01 \pm 6.98 \times 10^9$  per liter); detection of bacteria in combination with additional pathogen fungals in sputum samples (adjusted  $P \leq 1.67 \times 10^{-2}$ , 26% ( $n = 74$ ), 95% CI: 16%, 36%); and increased application of medication, including antifungals (adjusted  $P \leq 1.30 \times 10^{-4}$ , 15% ( $n = 74$ ), 95% CI: 7%, 23%) and catecholamines (adjusted  $P \leq 2.0 \times 10^{-2}$ , 45% ( $n = 74$ ), 95% CI: 33%, 56%). Patients in the ‘mild pneumonia’ group were characterized by positive sputum cultures in the presence of relatively lower inflammation

markers, such as PCT (adjusted  $P \leq 1.63 \times 10^{-3}$ ,  $1.42 \pm 2.03 \text{ ng ml}^{-1}$ ) and CRP (adjusted  $P \leq 0.03 \times 10^{-1}$ ,  $50.60 \pm 37.58 \text{ mg L}^{-1}$ ), while receiving antibiotics more frequently (adjusted  $P \leq 1.00 \times 10^{-5}$ , 80% ( $n = 78$ ), 95% CI: 70%, 89%) and additional medications (electrolytes, blood thinners and circulation-supporting medications) (adjusted  $P \leq 1.00 \times 10^{-5}$ , 82% ( $n = 78$ ), 95% CI: 73%, 91%). Finally, patients in the ‘viral pneumonia’ group were characterized by shorter LOSs (adjusted  $P \leq 8.00 \times 10^{-6}$ ,  $15.01 \pm 29.24$  d), a lack of non-viral pathogen detection in combination with higher lymphocyte counts (adjusted  $P \leq 0.01$ ,  $4.11 \pm 2.49 \times 10^9$  per liter), lower levels of PCT (adjusted  $P \leq 0.03 \times 10^{-2}$ ,  $1.42 \pm 2.03 \text{ ng ml}^{-1}$ ) and reduced application of catecholamines (adjusted  $P \leq 5.96 \times 10^{-7}$ , 15% ( $n = 97$ ), 95% CI: 8%, 23%), antibiotics (adjusted  $P \leq 8.53 \times 10^{-6}$ , 41% ( $n = 97$ ), 95% CI: 31%, 51%) and antifungals (adjusted  $P \leq 5.96 \times 10^{-7}$ , 0% ( $n = 97$ ), 95% CI: 0%, 0%).

To demonstrate the ability of ehrapy to examine EHR data from different levels of resolution, we additionally reconstructed a case from the ‘severe pneumonia with co-infection’ group (Fig. 2g). In this case, the analysis revealed that CRP levels remained elevated despite broad-spectrum antibiotic treatment until a positive *Acinetobacter baumannii* result led to a change in medication and a subsequent decrease in CRP and monocyte levels.

### ehrapy facilitates extraction of pneumonia indicators


ehrapy’s survival analysis module allowed us to identify clinical indicators of disease stages that could be used as biomarkers through Kaplan–Meier analysis. We found strong variance in overall aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT) and bilirubin levels (Fig. 3a), including changes over time (Extended Data Fig. 6a,b), in all four ‘unspecified pneumonia’ groups. Routinely used to assess liver function, studies provide evidence that AST, ALT and GGT levels are elevated during respiratory infections<sup>63</sup>, including severe pneumonia<sup>64</sup>, and can guide diagnosis and management of pneumonia in children<sup>63</sup>. We confirmed reduced survival in more severely affected children (‘sepsis-like pneumonia’ and ‘severe pneumonia with co-infection’) using Kaplan–Meier curves and a multivariate log-rank test (Fig. 3b;  $P \leq 1.09 \times 10^{-18}$ ) through ehrapy. To verify the association of this trajectory with altered AST, ALT and GGT expression levels, we further grouped all patients based on liver enzyme reference ranges (Methods and Supplementary Table 2). By Kaplan–Meier survival analysis, cases with peaks of GGT ( $P \leq 1.4 \times 10^{-2}$ ,  $58.01 \pm 2.03 \text{ U L}^{-1}$ ), ALT ( $P \leq 2.9 \times 10^{-2}$ ,  $43.59 \pm 38.02 \text{ U L}^{-1}$ ) and AST ( $P \leq 4.8 \times 10^{-4}$ ,  $78.69 \pm 60.03 \text{ U L}^{-1}$ ) in ‘outside the norm’ were found to correlate with lower survival in all groups (Fig. 3c and Extended Data Fig. 6), in line with previous studies<sup>63,65</sup>. Bilirubin was not found to significantly affect survival ( $P \leq 2.1 \times 10^{-1}$ ,  $12.57 \pm 21.22 \text{ mg dl}^{-1}$ ).

### ehrapy quantifies medication class effect on LOS

Pneumonia requires case-specific medications due to its diverse causes. To demonstrate the potential of ehrapy’s causal inference module, we quantified the effect of medication on ICU LOS to evaluate case-specific administration of medication. In contrast to causal discovery that attempts to find a causal graph reflecting the causal relationships, causal inference is a statistical process used to investigate possible effects when altering a provided system, as represented by a causal graph and observational data (Fig. 4a)<sup>66</sup>. This approach allows identifying and quantifying the impact of specific interventions or treatments on outcome measures, thereby providing insight for evidence-based decision-making in healthcare. Causal inference relies on datasets incorporating interventions to accurately quantify effects.


We manually constructed a minimal causal graph with ehrapy (Fig. 4b) on records of treatment with corticosteroids, carbapenems, penicillins, cephalosporins and antifungal and antiviral medications as interventions (Extended Data Fig. 7 and Methods). We assumed that the medications affect disease progression proxies, such as inflammation markers and markers of organ function. The selection of ‘interventions’





**Fig. 2 | PIC dataset overview and annotation of patients diagnosed with unspecified pneumonia.** **a**, UMAP of all patient visits in the ICU with primary discharge diagnosis grouped by ICD chapter. **b**, The prevalence of respiratory diseases prompted us to investigate them further. **c**, Respiratory categories show the abundance of influenza and pneumonia diagnoses that we investigated more closely. **d**, We observed the ‘unspecified pneumonia’ subgroup, which led

us to investigate and annotate it in more detail. **e**, The previously ‘unspecified pneumonia’-labeled patients were annotated using several clinical features (Extended Data Fig. 5), of which the most important ones are shown in the heatmap (**f**). **g**, Example disease progression of an individual child with pneumonia illustrating pharmacotherapy over time until positive *A. baumannii* swab.



**Fig. 3 | Survival analysis of patients diagnosed with unspecified pneumonia.** **a**, Line plots of major hepatic system laboratory measurements per group show variance in the measurements per pneumonia group. **b**, Kaplan-Meier survival

curves demonstrate lower survival for 'sepsis-like' and 'severe pneumonia with co-infection' groups. **c**, Kaplan-Meier survival curves for children with GGT measurements outside the norm range display lower survival.


is consistent with current treatment standards for bacterial pneumonia and respiratory distress<sup>67,68</sup>. Based on the approach of the tool 'dowhy'<sup>69</sup> (Fig. 4a), ehrapy's causal module identified the application of corticosteroids, antivirals and carbapenems to be associated with shorter LOSs, in line with current evidence<sup>61,70–72</sup>. In contrast, penicillins and cephalosporins were associated with longer LOSs, whereas antifungal medication did not strongly influence LOS (Fig. 4c).

### ehrapy enables deriving population-scale risk factors

To illustrate the advantages of using a unified data management and quality control framework, such as ehrapy, we modeled myocardial infarction risk using Cox proportional hazards models on UKB<sup>44</sup> data. Large population cohort studies, such as the UKB, enable the investigation of common diseases across a wide range of modalities, including genomics, metabolomics, proteomics, imaging data and common clinical variables (Fig. 5a,b). From these, we used a publicly available polygenic risk score for coronary heart disease<sup>73</sup> comprising 6.6 million variants, 80 nuclear magnetic resonance (NMR) spectroscopy-based metabolomics<sup>74</sup> features, 81 features derived from retinal optical coherence tomography<sup>75,76</sup> and the Framingham Risk Score<sup>77</sup> feature set, which includes known clinical predictors, such as age, sex, body mass

index, blood pressure, smoking behavior and cholesterol levels. We excluded features with more than 10% missingness and imputed the remaining missing values (Methods). Furthermore, individuals with events up to 1 year after the sampling time were excluded from the analyses, ultimately selecting 29,216 individuals for whom all mentioned data types were available (Extended Data Figs. 8 and 9 and Methods). Myocardial infarction, as defined by our mapping to the phecode nomenclature<sup>51</sup>, was defined as the endpoint (Fig. 5c). We modeled the risk for myocardial infarction 1 year after either the metabolomic sample was obtained or imaging was performed.

Predictive performance for each modality was assessed by fitting Cox proportional hazards (Fig. 5c) models on each of the feature sets using ehrapy (Fig. 5d). The age of the first occurrence served as the time to event; alternatively, date of death or date of the last record in the EHR served as censoring times. Models were evaluated using the concordance index (C-index) (Methods). The combination of multiple modalities successfully improved the predictive performance for coronary heart disease by increasing the C-index from 0.63 (genetic) to 0.76 (genetics, age and sex) and to 0.77 (clinical predictors) with 0.81 (imaging and clinical predictors) for combinations of feature sets (Fig. 5e). Our finding is in line with previous observations of complementary



**Fig. 4 | Causal inference of LOS affected by different medication types.**

**a**, ehrapy's causal module is based on the strategy of the tool 'dowhy'. Here, EHR data containing treatment, outcome and measurements and a causal graph serve as input for causal effect quantification. The process includes the identification of the target estimand based on the causal graph, the estimation of causal effects using various models and, finally, refutation where sensitivity

analyses and refutation tests are performed to assess the robustness of the results and assumptions. **b**, Curated causal graph using age, liver damage and inflammation markers as disease progression proxies together with medications as interventions to assess the causal effect on length of ICU stay. **c**, Determined causal effect strength on LOS in days of administered medication categories.

effects between different modalities, where a broader 'major adverse cardiac event' phenotype was modeled in the UKB achieving a C-index of 0.72 (ref. 78). Adding genetic data improves predictive potential, as it is independent of sampling age and has limited prediction of other modalities<sup>79</sup>. The addition of metabolomic data did not improve predictive power (Fig. 5e).

### Imaging-based disease severity projection via fate mapping

To demonstrate ehrapy's ability to handle diverse image data and recover disease stages, we embedded pulmonary imaging data obtained from patients with COVID-19 into a lower-dimensional space and computationally inferred disease progression trajectories using pseudotemporal ordering. This describes a continuous trajectory or ordering of individual points based on feature similarity<sup>80</sup>. Continuous trajectories enable mapping the fate of new patients onto precise states to potentially predict their future condition.

In COVID-19, a highly contagious respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), symptoms range from mild flu-like symptoms to severe respiratory distress. Chest x-rays typically show opacities (bilateral patchy, ground glass) associated with disease severity<sup>81</sup>.

We used COVID-19 chest x-ray images from the BrixIA<sup>82</sup> dataset consisting of 192 images (Fig. 6a) with expert annotations of disease severity. We used the BrixIA database scores, which are based on six regions annotated by radiologists, to classify


disease severity (Methods). We embedded raw image features using a pre-trained DenseNet model (Methods) and further processed this embedding into a nearest-neighbors-based UMAP space using ehrapy (Fig. 6b and Methods). Fate mapping based on imaging information (Methods) determined a severity ordering from mild to critical cases (Fig. 6b–d). Images labeled as 'normal' are projected to stay within the healthy group, illustrating the robustness of our approach. Images of diseased patients were ordered by disease severity, highlighting clear trajectories from 'normal' to 'critical' states despite the heterogeneity of the x-ray images stemming from, for example, different zoom levels (Fig. 6a).

### Detecting and mitigating biases in EHR data with ehrapy

To showcase how exploratory analysis using ehrapy can reveal and mitigate biases, we analyzed the Fairlearn<sup>83</sup> version of the Diabetes 130-US Hospitals<sup>84</sup> dataset. The dataset covers 10 years (1999–2008) of clinical records from 130 US hospitals, detailing 47 features of diabetes diagnoses, laboratory tests, medications and additional data from up to 14 d of inpatient care of 101,766 diagnosed patient visits (Methods). It was originally collected to explore the link between the measurement of hemoglobin A1c (HbA1c) and early readmission.

The cohort primarily consists of White and African American individuals, with only a minority of cases from Asian or Hispanic backgrounds (Extended Data Fig. 10a). ehrapy's cohort tracker unveiled selection and surveillance biases when filtering for Medicare recipients





**Fig. 5 | Analysis of myocardial infarction risk in the UKB.** **a**, The UKB includes 502,359 participants from 22 assessment centers. Most participants have genetic data (97%) and physical measurement data (93%), but fewer have data for complex measures, such as metabolomics, retinal imaging or proteomics. **b**, We found a distinct cluster of individuals (bottom right) from the Birmingham assessment center in the retinal imaging data, which is an artifact of the image acquisition process and was, thus, excluded. **c**, Myocardial infarctions are recorded for 15% of the male and 7% of the female study population.


Kaplan–Meier estimators with 95% CIs are shown. **d**, For every modality combination, a linear Cox proportional hazards model was fit to determine the prognostic potential of these for myocardial infarction. Cardiovascular risk factors show expected positive log hazard ratios (log (HRs)) for increased blood pressure or total cholesterol and negative ones for sampling age and systolic blood pressure (BP). log (HRs) with 95% CIs are shown. **e**, Combining all features yields a C-index of 0.81. **c–e**, Error bars indicate 95% CIs ( $n = 29,216$ ).

for further analysis, resulting in a shift of age distribution toward an age of over 60 years in addition to an increasing ratio of White participants. Using ehrapy's visualization modules, our analysis showed that HbA1c was measured in only 18.4% of inpatients, with a higher frequency in emergency admissions compared to referral cases (Extended Data Fig. 10b). Normalization biases can skew data relationships when standardization techniques ignore subgroup variability or assume incorrect distributions. The choice of normalization strategy must be carefully considered to avoid obscuring important factors. When normalizing the number of applied medications individually, differences in distributions between age groups remained. However, when normalizing both distributions jointly with age group as an additional group variable, differences between age groups were masked (Extended Data Fig. 10c). To investigate missing data and imputation biases, we introduced missingness for the number of applied medications according to an MCAR mechanism, which we verified using ehrapy's Little's test ( $P \leq 0.01 \times 10^{-2}$ ), and an MAR mechanism (Methods). Whereas imputing the mean in the MCAR case did not affect the overall location of the distribution, it led to an underestimation of the variance, with the standard deviation dropping from 8.1 in the original data to 6.8 in the imputed data (Extended Data Fig. 10d). Mean imputation in the MAR case skewed both location and variance of the mean from 16.02 to 14.66, with a standard deviation of only 5.72 (Extended Data Fig. 10d). Using ehrapy's multiple imputation based MissForest<sup>85</sup> imputation on the MAR data resulted in a mean of 16.04 and a standard deviation of 6.45.

To predict patient readmission in fewer than 30 d, we merged the three smallest race groups, 'Asian', 'Hispanic' and 'Other'. Furthermore, we dropped the gender group 'Unknown/Invalid' owing to the small sample size making meaningful assessment impossible, and we performed balanced random undersampling, resulting in 5,677 cases from each condition. We observed an overall balanced accuracy of 0.59 using a logistic regression model. However, the false-negative rate was highest for the races 'Other' and 'Unknown', whereas their selection rate was lowest, and this model was, therefore, biased (Extended Data Fig. 10e). Using ehrapy's compatibility with existing machine learning packages, we used Fairlearn's ThresholdOptimizer (Methods), which improved the selection rates for 'Other' from 0.32 to 0.38 and for 'Unknown' from 0.23 to 0.42 and the false-negative rates for 'Other' from 0.48 to 0.42 and for 'Unknown' from 0.61 to 0.45 (Extended Data Fig. 10e).

## Discussion

Clustering offers a hypothesis-free alternative to supervised classification when clear hypotheses or labels are missing. It has enabled the identification of heart failure subtypes<sup>86</sup> and progression pathways<sup>87</sup> and COVID-19 severity states<sup>88</sup>. This concept, which is central to ehrapy, further allowed us to identify fine-grained groups of 'unspecified pneumonia' cases in the PIC dataset while discovering biomarkers and quantifying effects of medications on LOS. Such retroactive characterization showcases ehrapy's ability to put complex evidence into context. This approach supports feedback loops to improve diagnostic and



**Fig. 6 | Recovery of disease severity trajectory in COVID-19 chest x-ray images.**

**a**, Randomly selected chest x-ray images from the BrixIA dataset demonstrate its variance. **b**, UMAP visualization of the BrixIA dataset embedding shows a separation

of disease severity classes. **c**, Calculated pseudotime for all images increases with distance to the 'normal' images. **d**, Stream projection of fate mapping in UMAP space showcases disease severity trajectory of the COVID-19 chest x-ray images.

therapeutic strategies, leading to more efficiently allocated resources in healthcare.

ehrapy's flexible data structures enabled us to integrate the heterogeneous UKB data for predictive performance in myocardial infarction. The different data types and distributions posed a challenge for predictive models that were overcome with ehrapy's pre-processing modules. Our analysis underscores the potential of combining phenotypic and health data at population scale through ehrapy to enhance risk prediction.

By adapting pseudotime approaches that are commonly used in other omics domains, we successfully recovered disease trajectories from raw imaging data with ehrapy. The determined pseudotime, however, only orders data but does not necessarily provide a future projection per patient. Understanding the driver features for fate mapping in image-based datasets is challenging. The incorporation of image segmentation approaches could mitigate this issue and provide a deeper insight into the spatial and temporal dynamics of disease-related processes.

Limitations of our analyses include the lack of control for informative missingness where the absence of information represents information in itself<sup>89</sup>. Translation from Chinese to English in the PIC database can cause information loss and inaccuracies because the Chinese ICD-10 codes are seven characters long compared to the five-character English codes. Incompleteness of databases, such as the lack of radiology images in the PIC database, low sample sizes, underrepresentation of non-White ancestries and participant self-selection, cannot be accounted for and limit generalizability. This restricts deeper phenotyping of, for example, all 'unspecified pneumonia' cases with respect to their survival, which could be overcome by the use of

multiple databases. Our causal inference use case is limited by unrecorded variables, such as Sequential Organ Failure Assessment (SOFA) scores, and pneumonia-related pathogens that are missing in the causal graph due to dataset constraints, such as high sparsity and substantial missing data, which risk overfitting and can lead to overinterpretation. We counterbalanced this by employing several refutation methods that statistically reject the causal hypothesis, such as a placebo treatment, a random common cause or an unobserved common cause. The longer hospital stays associated with penicillins and cephalosporins may be dataset specific and stem from higher antibiotic resistance, their use as first-line treatments, more severe initial cases, comorbidities and hospital-specific protocols.

Most analysis steps can introduce algorithmic biases where results are misleading or unfavorably affect specific groups. This is particularly relevant in the context of missing data<sup>22</sup> where determining the type of missing data is necessary to handle it correctly. ehrapy includes an implementation of Little's test<sup>90</sup>, which tests whether data are distributed MCAR to discern missing data types. For MCAR data single-imputation approaches, such as mean, median or mode, imputation can suffice, but these methods are known to reduce variability<sup>91,92</sup>. Multiple imputation strategies, such as Multiple Imputation by Chained Equations (MICE)<sup>93</sup> and MissForest<sup>85</sup>, as implemented in ehrapy, are effective for both MCAR and MAR data<sup>22,94,95</sup>. MNAR data require pattern-mixture or shared-parameter models that explicitly incorporate the mechanism by which data are missing<sup>96</sup>. Because MNAR involves unobserved data, the assumptions about the missingness mechanism cannot be directly verified, making sensitivity analysis crucial<sup>21</sup>. ehrapy's wide range of normalization functions and grouping functionality enables to account for intrinsic variability

within subgroups, and its compatibility with Fairlearn<sup>83</sup> can potentially mitigate predictor biases. Generally, we recommend to assess all pre-processing in an iterative manner with respect to downstream applications, such as patient stratification. Moreover, sensitivity analysis can help verify the robustness of all inferred knowledge<sup>97</sup>.

These diverse use cases illustrate ehrapy's potential to sufficiently address the need for a computationally efficient, extendable, reproducible and easy-to-use framework. ehrapy is compatible with major standards, such as Observational Medical Outcomes Partnership (OMOP), Common Data Model (CDM)<sup>47</sup>, HL7, FHIR or openEHR, with flexible support for common tabular data formats. Once loaded into an AnnData object, subsequent sharing of analysis results is made easy because AnnData objects can be stored and read platform independently. ehrapy's rich documentation of the application programming interface (API) and extensive hands-on tutorials make EHR analysis accessible to both novices and experienced analysts.

As ehrapy remains under active development, users can expect ehrapy to continuously evolve. We are improving support for the joint analysis of EHR, genetics and molecular data where ehrapy serves as a bridge between the EHR and the omics communities. We further anticipate the generation of EHR-specific reference datasets, so-called atlases<sup>98</sup>, to enable query-to-reference mapping where new datasets get contextualized by transferring annotations from the reference to the new dataset. To promote the sharing and collective analysis of EHR data, we envision adapted versions of interactive single-cell data explorers, such as CELLxGENE<sup>99</sup> or the UCSC Cell Browser<sup>100</sup>, for EHR data. Such web interfaces would also include disparity dashboards<sup>20</sup> to unveil trends of preferential outcomes for distinct patient groups. Additional modules specifically for high-frequency time-series data, natural language processing and other data types are currently under development. With the widespread availability of code-generating large language models, frameworks such as ehrapy are becoming accessible to medical professionals without coding expertise who can leverage its analytical power directly. Therefore, ehrapy, together with a lively ecosystem of packages, has the potential to enhance the scientific discovery pipeline to shape the era of EHR analysis.

## Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-024-03214-0>.

## References

- Goldberger, A. L. et al. PhysioBank, PhysioToolkit, and PhysioNet: components of a new research resource for complex physiologic signals. *Circulation* **101**, E215–E220 (2000).
- Atasoy, H., Greenwood, B. N. & McCullough, J. S. The digitization of patient care: a review of the effects of electronic health records on health care quality and utilization. *Annu. Rev. Public Health* **40**, 487–500 (2019).
- Jamoom, E. W., Patel, V., Furukawa, M. F. & King, J. EHR adopters vs. non-adopters: impacts of, barriers to, and federal initiatives for EHR adoption. *Health (Amst.)* **2**, 33–39 (2014).
- Rajkomar, A. et al. Scalable and accurate deep learning with electronic health records. *NPJ Digit. Med.* **1**, 18 (2018).
- Wolf, A. et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. *Int. J. Epidemiol.* **48**, 1740–1740g (2019).
- Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
- Pollard, T. J. et al. The eICU Collaborative Research Database, a freely available multi-center database for critical care research. *Sci. Data* **5**, 180178 (2018).
- Johnson, A. E. W. et al. MIMIC-III, a freely accessible critical care database. *Sci. Data* **3**, 160035 (2016).
- Hyland, S. L. et al. Early prediction of circulatory failure in the intensive care unit using machine learning. *Nat. Med.* **26**, 364–373 (2020).
- Rasmy, L. et al. Recurrent neural network models (CovRNN) for predicting outcomes of patients with COVID-19 on admission to hospital: model development and validation using electronic health record data. *Lancet Digit. Health* **4**, e415–e425 (2022).
- Marcus, J. L. et al. Use of electronic health record data and machine learning to identify candidates for HIV pre-exposure prophylaxis: a modelling study. *Lancet HIV* **6**, e688–e695 (2019).
- Kruse, C. S., Stein, A., Thomas, H. & Kaur, H. The use of electronic health records to support population health: a systematic review of the literature. *J. Med. Syst.* **42**, 214 (2018).
- Sheikh, A., Jha, A., Cresswell, K., Greaves, F. & Bates, D. W. Adoption of electronic health records in UK hospitals: lessons from the USA. *Lancet* **384**, 8–9 (2014).
- Sheikh, A. et al. Health information technology and digital innovation for national learning health and care systems. *Lancet Digit. Health* **3**, e383–e396 (2021).
- Cord, K. A. M., Mc Cord, K. A. & Hemkens, L. G. Using electronic health records for clinical trials: where do we stand and where can we go? *Can. Med. Assoc. J.* **191**, E128–E133 (2019).
- Landi, I. et al. Deep representation learning of electronic health records to unlock patient stratification at scale. *NPJ Digit. Med.* **3**, 96 (2020).
- Ayaz, M., Pasha, M. F., Alzahrani, M. Y., Budiarto, R. & Stiawan, D. The Fast Health Interoperability Resources (FHIR) standard: systematic literature review of implementations, applications, challenges and opportunities. *JMIR Med. Inform.* **9**, e21929 (2021).
- Peskoe, S. B. et al. Adjusting for selection bias due to missing data in electronic health records-based research. *Stat. Methods Med. Res.* **30**, 2221–2238 (2021).
- Haneuse, S. & Daniels, M. A general framework for considering selection bias in EHR-based studies: what data are observed and why? *EGEMS (Wash. DC)* **4**, 1203 (2016).
- Gallifant, J. et al. Disparity dashboards: an evaluation of the literature and framework for health equity improvement. *Lancet Digit. Health* **5**, e831–e839 (2023).
- Sauer, C. M. et al. Leveraging electronic health records for data science: common pitfalls and how to avoid them. *Lancet Digit. Health* **4**, e893–e898 (2022).
- Li, J. et al. Imputation of missing values for electronic health record laboratory data. *NPJ Digit. Med.* **4**, 147 (2021).
- Rubin, D. B. Inference and missing data. *Biometrika* **63**, 581 (1976).
- Scheid, L. M., Brown, L. S., Clark, C. & Rosenfeld, C. R. Data electronically extracted from the electronic health record require validation. *J. Perinatol.* **39**, 468–474 (2019).
- Phelan, M., Bhavsar, N. A. & Goldstein, B. A. Illustrating informed presence bias in electronic health records data: how patient interactions with a health system can impact inference. *EGEMS (Wash. DC)* **5**, 22 (2017).
- Secondary Analysis of Electronic Health Records* (ed MIT Critical Data) (Springer, 2016).
- Jetley, G. & Zhang, H. Electronic health records in IS research: quality issues, essential thresholds and remedial actions. *Decis. Support Syst.* **126**, 113137 (2019).
- McCormack, J. P. & Holmes, D. T. Your results may vary: the imprecision of medical measurements. *BMJ* **368**, m149 (2020).
- Hobbs, F. D. et al. Is the international normalised ratio (INR) reliable? A trial of comparative measurements in hospital laboratory and primary care settings. *J. Clin. Pathol.* **52**, 494–497 (1999).



30. Huguet, N. et al. Using electronic health records in longitudinal studies: estimating patient attrition. *Med. Care* **58** Suppl 6 Suppl 1, S46–S52 (2020).
31. Zeng, J., Gensheimer, M. F., Rubin, D. L., Athey, S. & Shachter, R. D. Uncovering interpretable potential confounders in electronic medical records. *Nat. Commun.* **13**, 1014 (2022).
32. Getzen, E., Ungar, L., Mowery, D., Jiang, X. & Long, Q. Mining for equitable health: assessing the impact of missing data in electronic health records. *J. Biomed. Inform.* **139**, 104269 (2023).
33. Tang, S. et al. Democratizing EHR analyses with FIDDLE: a flexible data-driven preprocessing pipeline for structured clinical data. *J. Am. Med. Inform. Assoc.* **27**, 1921–1934 (2020).
34. Dagliati, A. et al. A process mining pipeline to characterize COVID-19 patients' trajectories and identify relevant temporal phenotypes from EHR data. *Front. Public Health* **10**, 815674 (2022).
35. Sun, Y. & Zhou, Y.-H. A machine learning pipeline for mortality prediction in the ICU. *Int. J. Digit. Health* **2**, 3 (2022).
36. Mandyam, A., Yoo, E. C., Soules, J., Laudanski, K. & Engelhardt, B. E. COP-E-CAT: cleaning and organization pipeline for EHR computational and analytic tasks. In *Proc. of the 12th ACM Conference on Bioinformatics, Computational Biology, and Health Informatics*. <https://doi.org/10.1145/3459930.3469536> (Association for Computing Machinery, 2021).
37. Gao, C. A. et al. A machine learning approach identifies unresolving secondary pneumonia as a contributor to mortality in patients with severe pneumonia, including COVID-19. *J. Clin. Invest.* **133**, e170682 (2023).
38. Makam, A. N. et al. The good, the bad and the early adopters: providers' attitudes about a common, commercial EHR. *J. Eval. Clin. Pract.* **20**, 36–42 (2014).
39. Amezcua, R. A. et al. Orchestrating single-cell analysis with Bioconductor. *Nat. Methods* **17**, 137–145 (2020).
40. Virshup, I. et al. The scverse project provides a computational ecosystem for single-cell omics data analysis. *Nat. Biotechnol.* **41**, 604–606 (2023).
41. Zou, Q. et al. Predicting diabetes mellitus with machine learning techniques. *Front. Genet.* **9**, 515 (2018).
42. Cios, K. J. & William Moore, G. Uniqueness of medical data mining. *Artif. Intell. Med.* **26**, 1–24 (2002).
43. Zeng, X. et al. PIC, a paediatric-specific intensive care database. *Sci. Data* **7**, 14 (2020).
44. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).
45. Lee, J. et al. Open-access MIMIC-II database for intensive care research. *Annu. Int. Conf. Proc. IEEE Eng. Med. Biol. Soc.* **2011**, 8315–8318 (2011).
46. Virshup, I., Rybakov, S., Theis, F. J., Angerer, P. & Alexander Wolf, F. anndata: annotated data. Preprint at *bioRxiv* <https://doi.org/10.1101/2021.12.16.473007> (2021).
47. Voss, E. A. et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. *J. Am. Med. Inform. Assoc.* **22**, 553–564 (2015).
48. Vasilevsky, N. A. et al. Mondo: unifying diseases for the world, by the world. Preprint at *medRxiv* <https://doi.org/10.1101/2022.04.13.22273750> (2022).
49. Harrison, J. E., Weber, S., Jakob, R. & Chute, C. G. ICD-11: an international classification of diseases for the twenty-first century. *BMC Med. Inform. Decis. Mak.* **21**, 206 (2021).
50. Köhler, S. et al. Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. *Nucleic Acids Res.* **47**, D1018–D1027 (2019).
51. Wu, P. et al. Mapping ICD-10 and ICD-10-CM codes to phecodes: workflow development and initial evaluation. *JMIR Med. Inform.* **7**, e14325 (2019).
52. Wolf, F. A., Angerer, P. & Theis, F. J. SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol.* **19**, 15 (2018).
53. Pedregosa, F. et al. Scikit-learn: machine learning in Python. *J. Mach. Learn. Res.* **12**, 2825–2830 (2011).
54. de Haan-Rietdijk, S., de Haan-Rietdijk, S., Kuppens, P. & Hamaker, E. L. What's in a day? A guide to decomposing the variance in intensive longitudinal data. *Front. Psychol.* **7**, 891 (2016).
55. Pedersen, E. S. L., Danquah, I. H., Petersen, C. B. & Tolstrup, J. S. Intra-individual variability in day-to-day and month-to-month measurements of physical activity and sedentary behaviour at work and in leisure-time among Danish adults. *BMC Public Health* **16**, 1222 (2016).
56. Roffey, D. M., Byrne, N. M. & Hills, A. P. Day-to-day variance in measurement of resting metabolic rate using ventilated-hood and mouthpiece & nose-clip indirect calorimetry systems. *JPEN J. Parenter. Nutr.* **30**, 426–432 (2006).
57. Haghverdi, L., Büttner, M., Wolf, F. A., Büttner, F. & Theis, F. J. Diffusion pseudotime robustly reconstructs lineage branching. *Nat. Methods* **13**, 845–848 (2016).
58. Lange, M. et al. CellRank for directed single-cell fate mapping. *Nat. Methods* **19**, 159–170 (2022).
59. Weiler, P., Lange, M., Klein, M., Pe'er, D. & Theis, F. CellRank 2: unified fate mapping in multiview single-cell data. *Nat. Methods* **21**, 1196–1205 (2024).
60. Zhang, S. et al. Cost of management of severe pneumonia in young children: systematic analysis. *J. Glob. Health* **6**, 010408 (2016).
61. Torres, A. et al. Pneumonia. *Nat. Rev. Dis. Prim.* **7**, 25 (2021).
62. Traag, V. A., Waltman, L. & van Eck, N. J. From Louvain to Leiden: guaranteeing well-connected communities. *Sci. Rep.* **9**, 5233 (2019).
63. Kamin, W. et al. Liver involvement in acute respiratory infections in children and adolescents—results of a non-interventional study. *Front. Pediatr.* **10**, 840008 (2022).
64. Shi, T. et al. Risk factors for mortality from severe community-acquired pneumonia in hospitalized children transferred to the pediatric intensive care unit. *Pediatr. Neonatol.* **61**, 577–583 (2020).
65. Dudnyk, V. & Pasik, V. Liver dysfunction in children with community-acquired pneumonia: the role of infectious and inflammatory markers. *J. Educ. Health Sport* **11**, 169–181 (2021).
66. Chappignon, M.-L. et al. Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia. *Nat. Commun.* **13**, 7652 (2022).
67. Grief, S. N. & Loza, J. K. Guidelines for the evaluation and treatment of pneumonia. *Prim. Care* **45**, 485–503 (2018).
68. Paul, M. Corticosteroids for pneumonia. *Cochrane Database Syst. Rev.* **12**, CD007720 (2017).
69. Sharma, A. & Kiciman, E. DoWhy: an end-to-end library for causal inference. Preprint at *arXiv* <https://doi.org/10.48550/ARXIV.2011.04216> (2020).
70. Khilnani, G. C. et al. Guidelines for antibiotic prescription in intensive care unit. *Indian J. Crit. Care Med.* **23**, S1–S63 (2019).
71. Harris, L. K. & Crannage, A. J. Corticosteroids in community-acquired pneumonia: a review of current literature. *J. Pharm. Technol.* **37**, 152–160 (2021).
72. Dou, L. et al. Decreased hospital length of stay with early administration of oseltamivir in patients hospitalized with influenza. *Mayo Clin. Proc. Innov. Qual. Outcomes* **4**, 176–182 (2020).
73. Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat. Genet.* **50**, 1219–1224 (2018).
74. Julkunen, H. et al. Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank. *Nat. Commun.* **14**, 604 (2023).
75. Ko, F. et al. Associations with retinal pigment epithelium thickness measures in a large cohort: results from the UK Biobank. *Ophthalmology* **124**, 105–117 (2017).

76. Patel, P. J. et al. Spectral-domain optical coherence tomography imaging in 67 321 adults: associations with macular thickness in the UK Biobank study. *Ophthalmology* **123**, 829–840 (2016).
77. D'Agostino Sr, R. B. et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation* **117**, 743–753 (2008).
78. Buerger, T. et al. Metabolomic profiles predict individual multidisease outcomes. *Nat. Med.* **28**, 2309–2320 (2022).
79. Xu, Y. et al. An atlas of genetic scores to predict multi-omic traits. *Nature* **616**, 123–131 (2023).
80. Saelens, W., Cannoodt, R., Todorov, H. & Saeys, Y. A comparison of single-cell trajectory inference methods. *Nat. Biotechnol.* **37**, 547–554 (2019).
81. Rousan, L. A., Eloheid, E., Karrar, M. & Khader, Y. Chest x-ray findings and temporal lung changes in patients with COVID-19 pneumonia. *BMC Pulm. Med.* **20**, 245 (2020).
82. Signoroni, A. et al. BS-Net: learning COVID-19 pneumonia severity on a large chest X-ray dataset. *Med. Image Anal.* **71**, 102046 (2021).
83. Bird, S. et al. Fairlearn: a toolkit for assessing and improving fairness in AI. <https://www.microsoft.com/en-us/research/publication/fairlearn-a-toolkit-for-assessing-and-improving-fairness-in-ai/> (2020).
84. Strack, B. et al. Impact of HbA1c measurement on hospital readmission rates: analysis of 70,000 clinical database patient records. *BioMed. Res. Int.* **2014**, 781670 (2014).
85. Stekhoven, D. J. & Bühlmann, P. MissForest—non-parametric missing value imputation for mixed-type data. *Bioinformatics* **28**, 112–118 (2012).
86. Banerjee, A. et al. Identifying subtypes of heart failure from three electronic health record sources with machine learning: an external, prognostic, and genetic validation study. *Lancet Digit. Health* **5**, e370–e379 (2023).
87. Nagamine, T. et al. Data-driven identification of heart failure disease states and progression pathways using electronic health records. *Sci. Rep.* **12**, 17871 (2022).
88. Da Silva Filho, J. et al. Disease trajectories in hospitalized COVID-19 patients are predicted by clinical and peripheral blood signatures representing distinct lung pathologies. Preprint at *bioRxiv* <https://doi.org/10.1101/2023.09.08.23295024> (2023).
89. Haneuse, S., Arterburn, D. & Daniels, M. J. Assessing missing data assumptions in EHR-based studies: a complex and underappreciated task. *JAMA Netw. Open* **4**, e210184 (2021).
90. Little, R. J. A. A test of missing completely at random for multivariate data with missing values. *J. Am. Stat. Assoc.* **83**, 1198–1202 (1988).
91. Jakobsen, J. C., Gluud, C., Wetterslev, J. & Winkel, P. When and how should multiple imputation be used for handling missing data in randomised clinical trials—a practical guide with flowcharts. *BMC Med. Res. Methodol.* **17**, 162 (2017).
92. Dziura, J. D., Post, L. A., Zhao, Q., Fu, Z. & Peduzzi, P. Strategies for dealing with missing data in clinical trials: from design to analysis. *Yale J. Biol. Med.* **86**, 343–358 (2013).
93. White, I. R., Royston, P. & Wood, A. M. Multiple imputation using chained equations: issues and guidance for practice. *Stat. Med.* **30**, 377–399 (2011).
94. Jäger, S., Allhorn, A. & Bießmann, F. A benchmark for data imputation methods. *Front. Big Data* **4**, 693674 (2021).
95. Waljee, A. K. et al. Comparison of imputation methods for missing laboratory data in medicine. *BMJ Open* **3**, e002847 (2013).
96. Ibrahim, J. G. & Molenberghs, G. Missing data methods in longitudinal studies: a review. *Test (Madr.)* **18**, 1–43 (2009).
97. Li, C., Alsheikh, A. M., Robinson, K. A. & Lehmann, H. P. Use of recommended real-world methods for electronic health record data analysis has not improved over 10 years. Preprint at *bioRxiv* <https://doi.org/10.1101/2023.06.21.23291706> (2023).
98. Regev, A. et al. The Human Cell Atlas. *eLife* **6**, e27041 (2017).
99. McGill, C. et al. cellxgene: a performant, scalable exploration platform for high dimensional sparse matrices. Preprint at *bioRxiv* <https://doi.org/10.1101/2021.04.05.438318> (2021).
100. Speir, M. L. et al. UCSC Cell Browser: visualize your single-cell data. *Bioinformatics* **37**, 4578–4580 (2021).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024

**Lukas Heumos<sup>1,2,3</sup>, Philipp Ehmele<sup>1</sup>, Tim Treis<sup>1,3</sup>, Julius Upmeyer zu Belzen<sup>4</sup>, Eljas Roellin<sup>1,5</sup>, Lilly May<sup>1,5</sup>, Altana Namsaraeva<sup>1,6</sup>, Nastassya Horlava<sup>1,3</sup>, Vladimir A. Shitov<sup>1,3</sup>, Xinyue Zhang<sup>1</sup>, Luke Zappia<sup>1,5</sup>, Rainer Knoll<sup>7</sup>, Niklas J. Lang<sup>2</sup>, Leon Hetzel<sup>1,5</sup>, Isaac Virshup<sup>1</sup>, Lisa Sikkema<sup>1,3</sup>, Fabiola Curion<sup>1,5</sup>, Roland Eils<sup>4,8</sup>, Herbert B. Schiller<sup>2,9</sup>, Anne Hilgendorff<sup>2,10</sup> & Fabian J. Theis<sup>1,3,5</sup>✉**

<sup>1</sup>Institute of Computational Biology, Helmholtz Munich, Munich, Germany. <sup>2</sup>Institute of Lung Health and Immunity and Comprehensive Pneumology Center with the CPC-M bioArchive; Helmholtz Zentrum Munich; member of the German Center for Lung Research (DZL), Munich, Germany. <sup>3</sup>TUM School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany. <sup>4</sup>Health Data Science Unit, Heidelberg University and BioQuant, Heidelberg, Germany. <sup>5</sup>Department of Mathematics, School of Computation, Information and Technology, Technical University of Munich, Munich, Germany. <sup>6</sup>Konrad Zuse School of Excellence in Learning and Intelligent Systems (ELIZA), Darmstadt, Germany. <sup>7</sup>Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany. <sup>8</sup>Center for Digital Health, Berlin Institute of Health (BIH) at Charité – Universitätsmedizin Berlin, Berlin, Germany. <sup>9</sup>Research Unit, Precision Regenerative Medicine (PRM), Helmholtz Munich, Munich, Germany. <sup>10</sup>Center for Comprehensive Developmental Care (CDeCLMU) at the Social Pediatric Center, Dr. von Hauner Children's Hospital, LMU Hospital, Ludwig Maximilian University, Munich, Germany. ✉e-mail: [fabian.theis@helmholtz-muenchen.de](mailto:fabian.theis@helmholtz-muenchen.de)

## Methods

All datasets that were used during the development of ehrapy and the use cases were used according to their terms of use as indicated by each provider.

### Design and implementation of ehrapy

A unified pipeline as provided by our ehrapy framework streamlines the analysis of EHR data by providing an efficient, standardized approach, which reduces the complexity and variability in data pre-processing and analysis. This consistency ensures reproducibility of results and facilitates collaboration and sharing within the research community. Additionally, the modular structure allows for easy extension and customization, enabling researchers to adapt the pipeline to their specific needs while building on a solid foundational framework.

ehrapy was designed from the ground up as an open-source effort with community support. The package, as well as all associated tutorials and dataset preparation scripts, are open source. Development takes place publicly on GitHub where the developers discuss feature requests and issues directly with users. This tight interaction between both groups ensures that we implement the most pressing needs to cater the most important use cases and can guide users when difficulties arise. The open-source nature, extensive documentation and modular structure of ehrapy are designed for other developers to build upon and extend ehrapy's functionality where necessary. This allows us to focus ehrapy on the most important features to keep the number of dependencies to a minimum.

ehrapy was implemented in the Python programming language and builds upon numerous existing numerical and scientific open-source libraries, specifically matplotlib<sup>101</sup>, seaborn<sup>102</sup>, NumPy<sup>103</sup>, numba<sup>104</sup>, SciPy<sup>105</sup>, scikit-learn<sup>53</sup> and Pandas<sup>106</sup>. Although taking considerable advantage of all packages implemented, ehrapy also shares the limitations of these libraries, such as a lack of GPU support or small performance losses due to the translation layer cost for operations between the Python interpreter and the lower-level C language for matrix operations. However, by building on very widely used open-source software, we ensure seamless integration and compatibility with a broad range of tools and platforms to promote community contributions. Additionally, by doing so, we enhance security by allowing a larger pool of developers to identify and address vulnerabilities<sup>107</sup>. All functions are grouped into task-specific modules whose implementation is complemented with additional dependencies.

### Data preparation

**Dataloaders.** ehrapy is compatible with any type of vectorized data, where vectorized refers to the data being stored in structured tables in either on-disk or database form. The input and output module of ehrapy provides readers for common formats, such as OMOP, CSV tables or SQL databases through Pandas. When reading in such datasets, the data are stored in the appropriate slots in a new AnnData<sup>46</sup> object. ehrapy's data module provides access to more than 20 public EHR datasets that feature diseases, including, but not limited to, Parkinson's disease, breast cancer, chronic kidney disease and more. All dataloaders return AnnData objects to allow for immediate analysis.

**AnnData for EHR data.** Our framework required a versatile data structure capable of handling various matrix formats, including Numpy<sup>103</sup> for general use cases and interoperability, SciPy<sup>105</sup> sparse matrices for efficient storage, Dask<sup>108</sup> matrices for larger-than-memory analysis and Awkward array<sup>109</sup> for irregular time-series data. We needed a single data structure that not only stores data but also includes comprehensive annotations for thorough contextual analysis. It was essential for this structure to be widely used and supported, which ensures robustness and continual updates. Interoperability with other analytical packages was a key criterion to facilitate seamless integration within existing tools and workflows. Finally, the data structure had to support both

in-memory operations and on-disk storage using formats such as HDF5 (ref. 110) and Zarr<sup>111</sup>, ensuring efficient handling and accessibility of large datasets and the ability to easily share them with collaborators.

All of these requirements are fulfilled by the AnnData format, which is a popular data structure in single-cell genomics. At its core, an AnnData object encapsulates diverse components, providing a holistic representation of data and metadata that are always aligned in dimensions and easily accessible. A data matrix (commonly referred to as 'X') stands as the foundational element, embodying the measured data. This matrix can be dense (as Numpy array), sparse (as SciPy sparse matrix) or ragged (as Awkward array) where dimensions do not align within the data matrix. The AnnData object can feature several such data matrices stored in 'layers'. Examples of such layers can be unnormalized or unencoded data. These data matrices are complemented by an observations (commonly referred to as 'obs') segment where annotations on the level of patients or visits are stored. Patients' age or sex, for instance, are often used as such annotations. The variables (commonly referred to as 'var') section complements the observations, offering supplementary details about the features in the dataset, such as missing data rates. The observation-specific matrices (commonly referred to as 'obsm') section extends the capabilities of the AnnData structure by allowing the incorporation of observation-specific matrices. These matrices can represent various types of information at the individual cell level, such as principal component analysis (PCA) results, t-distributed stochastic neighbor embedding (t-SNE) coordinates or other dimensionality reduction outputs. Analogously, AnnData features a variables-specific variables (commonly referred to as 'varm') component. The observation-specific pairwise relationships (commonly referred to as 'obsp') segment complements the 'obsm' section by accommodating observation-specific pairwise relationships. This can include connectivity matrices, indicating relationships between patients. The inclusion of an unstructured annotations (commonly referred to as 'uns') component further enhances flexibility. This segment accommodates unstructured annotations or arbitrary data that might not conform to the structured observations or variables categories. Any AnnData object can be stored on disk in h5ad or Zarr format to facilitate data exchange.

ehrapy natively interfaces with the scientific Python ecosystem via Pandas<sup>112</sup> and Numpy<sup>103</sup>. The development of deep learning models for EHR data<sup>113</sup> is further accelerated through compatibility with pathml<sup>114</sup>, a unified framework for whole-slide image analysis in pathology, and scvi-tools<sup>115</sup>, which provides data loaders for loading tensors from AnnData objects into PyTorch<sup>116</sup> or Jax arrays<sup>117</sup> to facilitate the development of generalizing foundational models for medical artificial intelligence<sup>118</sup>.

**Feature annotation.** After AnnData creation, any metadata can be mapped against ontologies using Bionty (<https://github.com/laminlabs/bionty-base>). Bionty provides access to the Human Phenotype, Phecodes, Phenotype and Trait, Drug, Mondo and Human Disease ontologies.

Key medical terms stored in an AnnData object in free text can be extracted using the Medical Concept Annotation Toolkit (MedCAT)<sup>119</sup>.

### Data processing

**Cohort tracking.** ehrapy provides a *CohortTracker* tool that traces all filtering steps applied to an associated AnnData object. To calculate cohort summary statistics, the implementation makes use of tableone<sup>120</sup> and can subsequently be plotted as bar charts together with flow diagrams<sup>121</sup> that visualize the order and reasoning of filtering operations.

**Basic pre-processing and quality control.** ehrapy encompasses a suite of functionalities for fundamental data processing that are adopted from scanpy<sup>52</sup> but adapted to EHR data:



1. **Regress out:** To address unwanted sources of variation, a regression procedure is integrated, enhancing the dataset's robustness.
2. **Subsample:** Selects a specified fraction of observations.
3. **Balanced sample:** Balances groups in the dataset by random oversampling or undersampling.
4. **Highly variable features:** The identification and annotation of highly variable features following the 'highly variable genes' function of scanpy is seamlessly incorporated, providing users with insights into pivotal elements influencing the dataset.

To identify and minimize quality issues, ehrapy provides several quality control functions:

1. **Basic quality control:** Determines the relative and absolute number of missing values per feature and per patient.
2. **Winsorization:** For data refinement, ehrapy implements a winsorization process, creating a version of the input array less susceptible to extreme values.
3. **Feature clipping:** Imposes limits on features to enhance dataset reliability.
4. **Detect biases:** Computes pairwise correlations between features, standardized mean differences for numeric features between groups of sensitive features, categorical feature value count differences between groups of sensitive features and feature importances when predicting a target variable.
5. **Little's MCAR test:** Applies Little's MCAR test whose null hypothesis is that data are MCAR. Rejecting the null hypothesis may not always mean that data are not MCAR, nor is accepting the null hypothesis a guarantee that data are MCAR. For more details, see Schouten et al.<sup>122</sup>.
6. **Summarize features:** Calculates statistical indicators per feature, including minimum, maximum and average values. This can be especially useful to reduce complex data with multiple measurements per feature per patient into sets of columns with single values.

Imputation is crucial in data analysis to address missing values, ensuring the completeness of datasets that can be required for specific algorithms. The 'ehrapy' pre-processing module offers a range of imputation techniques:

1. **Explicit Impute:** Replaces missing values, in either all columns or a user-specified subset, with a designated replacement value.
2. **Simple Impute:** Imputes missing values in numerical data using mean, median or the most frequent value, contributing to a more complete dataset.
3. **KNN Impute:** Uses *k*-nearest neighbor imputation to fill in missing values in the input AnnData object, preserving local data patterns.
4. **MissForest Impute:** Implements the MissForest strategy for imputing missing data, providing a robust approach for handling complex datasets.
5. **MICE Impute:** Applies the MICE algorithm for imputing data. This implementation is based on the miceforest (<https://github.com/AnotherSamWilson/miceforest>) package.

Data encoding can be required if categoricals are a part of the dataset to obtain numerical values only. Most algorithms in ehrapy are compatible only with numerical values. ehrapy offers two encoding algorithms based on scikit-learn<sup>53</sup>:

1. **One-Hot Encoding:** Transforms categorical variables into binary vectors, creating a binary feature for each category and capturing the presence or absence of each category in a concise representation.

2. **Label Encoding:** Assigns a unique numerical label to each category, facilitating the representation of categorical data as ordinal values and supporting algorithms that require numerical input.

To ensure that the distributions of the heterogeneous data are aligned, ehrapy offers several normalization procedures:

1. **Log Normalization:** Applies the natural logarithm function to the data, useful for handling skewed distributions and reducing the impact of outliers.
2. **Max-Abs Normalization:** Scales each feature by its maximum absolute value, ensuring that the maximum absolute value for each feature is 1.
3. **Min-Max Normalization:** Transforms the data to a specific range (commonly (0, 1)) by scaling each feature based on its minimum and maximum values.
4. **Power Transformation Normalization:** Applies a power transformation to make the data more Gaussian like, often useful for stabilizing variance and improving the performance of models sensitive to distributional assumptions.
5. **Quantile Normalization:** Aligns the distributions of multiple variables, ensuring that their quantiles match, which can be beneficial for comparing datasets or removing batch effects.
6. **Robust Scaling Normalization:** Scales data using the interquartile range, making it robust to outliers and suitable for datasets with extreme values.
7. **Scaling Normalization:** Standardizes data by subtracting the mean and dividing by the standard deviation, creating a distribution with a mean of 0 and a standard deviation of 1.
8. **Offset to Positive Values:** Shifts all values by a constant offset to make all values non-negative, with the lowest negative value becoming 0.

Dataset shifts can be corrected using the scanpy implementation of the ComBat<sup>123</sup> algorithm, which employs a parametric and non-parametric empirical Bayes framework for adjusting data for batch effects that is robust to outliers.

Finally, a neighbors graph can be efficiently computed using scanpy's implementation.

**Embeddings.** To obtain meaningful lower-dimensional embeddings that can subsequently be visualized and reused for downstream algorithms, ehrapy provides the following algorithms based on scanpy's implementation:

1. **t-SNE:** Uses a probabilistic approach to embed high-dimensional data into a lower-dimensional space, emphasizing the preservation of local similarities and revealing clusters in the data.
2. **UMAP:** Embeds data points by modeling their local neighborhood relationships, offering an efficient and scalable technique that captures both global and local structures in high-dimensional data.
3. **Force-Directed Graph Drawing:** Uses a physical simulation to position nodes in a graph, with edges representing pairwise relationships, creating a visually meaningful representation that emphasizes connectedness and clustering in the data.
4. **Diffusion Maps:** Applies spectral methods to capture the intrinsic geometry of high-dimensional data by modeling diffusion processes, providing a way to uncover underlying structures and patterns.
5. **Density Calculation in Embedding:** Quantifies the density of observations within an embedding, considering conditions or groups, offering insights into the concentration of data points in different regions and aiding in the identification of densely populated areas.

**Clustering.** ehrapy further provides algorithms for clustering and trajectory inference based on scanpy:

1. Leiden Clustering: Uses the Leiden algorithm to cluster observations into groups, revealing distinct communities within the dataset with an emphasis on intra-cluster cohesion.
2. Hierarchical Clustering Dendrogram: Constructs a dendrogram through hierarchical clustering based on specified group by categories, illustrating the hierarchical relationships among observations and facilitating the exploration of structured patterns.

**Feature ranking.** ehrapy provides two ways of ranking feature contributions to clusters and target variables:

1. Statistical tests: To compare any obtained clusters to obtain marker features that are significantly different between the groups, ehrapy extends scanpy's 'rank genes groups'. The original implementation, which features a *t*-test for numerical data, is complemented by a *g*-test for categorical data.
2. Feature importance: Calculates feature rankings for a target variable using linear regression, support vector machine or random forest models from scikit-learn. ehrapy evaluates the relative importance of each predictor by fitting the model and extracting model-specific metrics, such as coefficients or feature importances.

**Dataset integration.** Based on scanpy's 'ingest' function, ehrapy facilitates the integration of labels and embeddings from a well-annotated reference dataset into a new dataset, enabling the mapping of cluster annotations and spatial relationships for consistent comparative analysis. This process ensures harmonized clinical interpretations across datasets, especially useful when dealing with multiple experimental diseases or batches.

### Knowledge inference

**Survival analysis.** ehrapy's implementation of survival analysis algorithms is based on lifelines<sup>124</sup>:

1. Ordinary Least Squares (OLS) Model: Creates a linear regression model using OLS from a specified formula and an AnnData object, allowing for the analysis of relationships between variables and observations.
2. Generalized Linear Model (GLM): Constructs a GLM from a given formula, distribution and AnnData, providing a versatile framework for modeling relationships with nonlinear data structures.
3. Kaplan–Meier: Fits the Kaplan–Meier curve to generate survival curves, offering a visual representation of the probability of survival over time in a dataset.
4. Cox Hazard Model: Constructs a Cox proportional hazards model using a specified formula and an AnnData object, enabling the analysis of survival data by modeling the hazard rates and their relationship to predictor variables.
5. Log-Rank Test: Calculates the *P* value for the log-rank test, comparing the survival functions of two groups, providing statistical significance for differences in survival distributions.
6. GLM Comparison: Given two fit GLMs, where the larger encompasses the parameter space of the smaller, this function returns the *P* value, indicating the significance of the larger model and adding explanatory power beyond the smaller model.

**Trajectory inference.** Trajectory inference is a computational approach that reconstructs and models the developmental paths and transitions within heterogeneous clinical data, providing insights into

the temporal progression underlying complex systems. ehrapy offers several inbuilt algorithms for trajectory inference based on scanpy:

1. Diffusion Pseudotime: Infers the progression of observations by measuring geodesic distance along the graph, providing a pseudotime metric that represents the developmental trajectory within the dataset.
2. Partition-based Graph Abstraction (PAGA): Maps out the coarse-grained connectivity structures of complex manifolds using a partition-based approach, offering a comprehensive visualization of relationships in high-dimensional data and aiding in the identification of macroscopic connectivity patterns.

Because ehrapy is compatible with scverse, further trajectory inference-based algorithms, such as CellRank, can be seamlessly applied.

**Causal inference.** ehrapy's causal inference module is based on 'dowhy'<sup>69</sup>. It is based on four key steps that are all implemented in ehrapy:

1. Graphical Model Specification: Define a causal graphical model representing relationships between variables and potential causal effects.
2. Causal Effect Identification: Automatically identify whether a causal effect can be inferred from the given data, addressing confounding and selection bias.
3. Causal Effect Estimation: Employ automated tools to estimate causal effects, using methods such as matching, instrumental variables or regression.
4. Sensitivity Analysis and Testing: Perform sensitivity analysis to assess the robustness of causal inferences and conduct statistical testing to determine the significance of the estimated causal effects.

**Patient stratification.** ehrapy's complete pipeline from pre-processing to the generation of lower-dimensional embeddings, clustering, statistical comparison between determined groups and more facilitates the stratification of patients.

### Visualization

ehrapy features an extensive visualization pipeline that is customizable and yet offers reasonable defaults. Almost every analysis function is matched with at least one visualization function that often shares the name but is available through the plotting module. For example, after importing ehrapy as 'ep', 'ep.tl.umap(adata)' runs the UMAP algorithm on an AnnData object, and 'ep.pl.umap(adata)' would then plot a scatter plot of the UMAP embedding.

ehrapy further offers a suite of more generally usable and modifiable plots:

1. Scatter Plot: Visualizes data points along observation or variable axes, offering insights into the distribution and relationships between individual data points.
2. Heatmap: Represents feature values in a grid, providing a comprehensive overview of the data's structure and patterns.
3. Dot Plot: Displays count values of specified variables as dots, offering a clear depiction of the distribution of counts for each variable.
4. Filled Line Plot: Illustrates trends in data with filled lines, emphasizing variations in values over a specified axis.
5. Violin Plot: Presents the distribution of data through mirrored density plots, offering a concise view of the data's spread.
6. Stacked Violin Plot: Combines multiple violin plots, stacked to allow for visual comparison of distributions across categories.

7. Group Mean Heatmap: Creates a heatmap displaying the mean count per group for each specified variable, providing insights into group-wise trends.
8. Hierarchically Clustered Heatmap: Uses hierarchical clustering to arrange data in a heatmap, revealing relationships and patterns among variables and observations.
9. Rankings Plot: Visualizes rankings within the data, offering a clear representation of the order and magnitude of values.
10. Dendrogram Plot: Plots a dendrogram of categories defined in a group by operation, illustrating hierarchical relationships within the dataset.

### Benchmarking ehrapy

We generated a subset of the UKB data selecting 261 features and 488,170 patient visits. We removed all features with missingness rates greater than 70%. To demonstrate speed and memory consumption for various scenarios, we subsampled the data to 20%, 30% and 50%. We ran a minimal ehrapy analysis pipeline on each of those subsets and the full data, including the calculation of quality control metrics, filtering of variables by a missingness threshold, nearest neighbor imputation, normalization, dimensionality reduction and clustering (Supplementary Table 1). We conducted our benchmark on a single CPU with eight threads and 60 GB of maximum memory.

ehrapy further provides out-of-core implementations using Dask<sup>108</sup> for many algorithms in ehrapy, such as our normalization functions or our PCA implementation. Out-of-core computation refers to techniques that process data that do not fit entirely in memory, using disk storage to manage data overflow. This approach is crucial for handling large datasets without being constrained by system memory limits. Because the principal components get reused for other computationally expensive algorithms, such as the neighbors graph calculation, it effectively enables the analysis of very large datasets. We are currently working on supporting out-of-core computation for all computationally expensive algorithms in ehrapy.

We demonstrate the memory benefits in a hosted tutorial where the in-memory pipeline for 50,000 patients with 1,000 features required about 2 GB of memory, and the corresponding out-of-core implementation required less than 200 MB of memory.

The code for benchmarking is available at <https://github.com/theislabs/ehrapy-reproducibility>. The implementation of ehrapy is accessible at <https://github.com/theislabs/ehrapy> together with extensive API documentation and tutorials at <https://ehrapy.readthedocs.io>.

### PIC database analysis

**Study design.** We collected clinical data from the PIC<sup>43</sup> version 1.1.0 database. PIC is a single-center, bilingual (English and Chinese) database hosting information of children admitted to critical care units at the Children's Hospital of Zhejiang University School of Medicine in China. The requirement for individual patient consent was waived because the study did not impact clinical care, and all protected health information was de-identified. The database contains 13,499 distinct hospital admissions of 12,881 distinct pediatric patients. These patients were admitted to five ICU units with 119 total critical care beds—GICU, PICU, SICU, CICU and NICU—between 2010 and 2018. The mean age of the patients was 2.5 years, of whom 42.5% were female. The in-hospital mortality was 7.1%; the mean hospital stay was 17.6 d; the mean ICU stay was 9.3 d; and 468 (3.6%) patients were admitted multiple times. Demographics, diagnoses, doctors' notes, laboratory and microbiology tests, prescriptions, fluid balances, vital signs and radiographics reports were collected from all patients. For more details, see the original publication of Zeng et al.<sup>43</sup>.

**Study participants.** Individuals older than 18 years were excluded from the study. We grouped the data into three distinct groups: 'neonates' (0–28 d of age; 2,968 patients), 'infants' (1–12 months of age; 4,876

patients) and 'youths' (13 months to 18 years of age; 6,097 patients). We primarily analyzed the 'youths' group with the discharge diagnosis 'unspecified pneumonia' (277 patients).

**Data collection.** The collected clinical data included demographics, laboratory and vital sign measurements, diagnoses, microbiology and medication information and mortality outcomes. The five-character English ICD-10 codes were used, whose values are based on the seven-character Chinese ICD-10 codes.

**Dataset extraction and analysis.** We downloaded the PIC database of version 1.1.0 from Physionet<sup>4</sup> to obtain 17 CSV tables. Using Pandas, we selected all information with more than 50% coverage rate, including demographics and laboratory and vital sign measurements (Fig. 2). To reduce the amount of noise, we calculated and added only the minimum, maximum and average of all measurements that had multiple values per patient. Examination reports were removed because they describe only diagnostics and not detailed findings. All further diagnoses and microbiology and medication information were included into the observations slot to ensure that the data were not used for the calculation of embeddings but were still available for the analysis. This ensured that any calculated embedding would not be divided into treated and untreated groups but, rather, solely based on phenotypic features. We imputed all missing data through *k*-nearest neighbors imputation (*k* = 20) using the *knn\_impute* function of ehrapy. Next, we log normalized the data with ehrapy using the *log\_norm* function. Afterwards, we winsorized the data using ehrapy's *winsorize* function to obtain 277 ICU visits (*n* = 265 patients) with 572 features. Of those 572 features, 254 were stored in the matrix *X* and the remaining 318 in the 'obs' slot in the AnnData object. For clustering and visualization purposes, we calculated 50 principal components using ehrapy's *pca* function. The obtained principal component representation was then used to calculate a nearest neighbors graph using the *neighbors* function of ehrapy. The nearest neighbors graph then served as the basis for a UMAP embedding calculation using ehrapy's *umap* function.

**Patient stratification.** We applied the community detection algorithm Leiden with resolution 0.6 on the nearest neighbor graph using ehrapy's *leiden* function. The four obtained clusters served as input for two-sided *t*-tests for all numerical values and two-sided *g*-tests for all categorical values for all four clusters against the union of all three other clusters, respectively. This was conducted using ehrapy's *rank\_feature\_groups* function, which also corrects *P* values for multiple testing with the Benjamini–Hochberg method<sup>125</sup>. We presented the four groups and the statistically significantly different features between the groups to two pediatricians who annotated the groups with labels.

Our determined groups can be confidently labeled owing to their distinct clinical profiles. Nevertheless, we could only take into account clinical features that were measured. Insightful features, such as lung function tests, are missing. Moreover, the feature representation of the time-series data is simplified, which can hide some nuances between the groups. Generally, deciding on a clustering resolution is difficult. However, more fine-grained clusters obtained via higher clustering resolutions may become too specific and not generalize well enough.

**Kaplan–Meier survival analysis.** We selected patients with up to 360 h of total stay for Kaplan–Meier survival analysis to ensure a sufficiently high number of participants. We proceeded with the AnnData object prepared as described in the 'Patient stratification' subsection to conduct Kaplan–Meier analysis among all four determined pneumonia groups using ehrapy's *kmf* function. Significance was tested through ehrapy's *test\_kmf\_logrank* function, which tests whether two Kaplan–Meier series are statistically significant, employing a chi-squared test statistic under the null hypothesis. Let  $h_i(t)$  be the



hazard ratio of group  $i$  at time  $t$  and  $c$  a constant that represents a proportional change in the hazard ratio between the two groups, then:

$$H_0 : h_1(t) = h_2(t)$$

$$H_a : h_1(t) = c * h_2(t), c \neq 1$$

This implicitly uses the log-rank weights. An additional Kaplan–Meier analysis was conducted for all children jointly concerning the liver markers AST, ALT and GGT. To determine whether measurements were inside or outside the norm range, we used reference ranges (Supplementary Table 2).  $P$  values less than 0.05 were labeled significant.

Our Kaplan–Meier curve analysis depends on the groups being well defined and shares the same limitations as the patient stratification. Additionally, the analysis is sensitive to the reference table where we selected limits that generalize well for the age ranges, but, due to children of different ages being examined, they may not necessarily be perfectly accurate for all children.

**Causal effect of mechanism of action on LOS.** Although the dataset was not initially intended for investigating causal effects of interventions, we adapted it for this purpose by focusing on the LOS in the ICU, measured in months, as the outcome variable. This choice aligns with the clinical aim of stabilizing patients sufficiently for ICU discharge. We constructed a causal graph to explore how different drug administrations could potentially reduce the LOS. Based on consultations with clinicians, we included several biomarkers of liver damage (AST, ALT and GGT) and inflammation (CRP and PCT) in our model. Patient age was also considered a relevant variable.

Because several different medications act by the same mechanisms, we grouped specific medications by their drug classes. This grouping was achieved by cross-referencing the drugs listed in the dataset with DrugBank release 5.1 (ref. 126), using Levenshtein distances for partial string matching. After manual verification, we extracted the corresponding DrugBank categories, counted the number of features per category and compiled a list of commonly prescribed medications, as advised by clinicians. This approach facilitated the modeling of the causal graph depicted in Fig. 4, where an intervention is defined as the administration of at least one drug from a specified category.

Causal inference was then conducted with ehrapy's 'dowhy'<sup>69</sup>-based causal inference module using the expert-curated causal graph. Medication groups were designated as causal interventions, and the LOS was the outcome of interest. Linear regression served as the estimation method for analyzing these causal effects. We excluded four patients from the analysis owing to their notably long hospital stays exceeding 90 d, which were deemed outliers. To validate the robustness of our causal estimates, we incorporated several refutation methods:

- **Placebo Treatment Refuter:** This method involved replacing the treatment assignment with a placebo to test the effect of the treatment variable being null.
- **Random Common Cause:** A randomly generated variable was added to the data to assess the sensitivity of the causal estimate to the inclusion of potential unmeasured confounders.
- **Data Subset Refuter:** The stability of the causal estimate was tested across various random subsets of the data to ensure that the observed effects were not dependent on a specific subset.
- **Add Unobserved Common Cause:** This approach tested the effect of an omitted variable by adding a theoretically relevant unobserved confounder to the model, evaluating how much an unmeasured variable could influence the causal relationship.
- **Dummy Outcome:** Replaces the true outcome variable with a random variable. If the causal effect nullifies, it supports the validity of the original causal relationship, indicating that the outcome is not driven by random factors.

- **Bootstrap Validation:** Employs bootstrapping to generate multiple samples from the dataset, testing the consistency of the causal effect across these samples.

The selection of these refuters addresses a broad spectrum of potential biases and model sensitivities, including unobserved confounders and data dependencies. This comprehensive approach ensures robust verification of the causal analysis. Each refuter provides an orthogonal perspective, targeting specific vulnerabilities in causal analysis, which strengthens the overall credibility of the findings.

## UKB analysis

**Study population.** We used information from the UKB cohort, which includes 502,164 study participants from the general UK population without enrichment for specific diseases. The study involved the enrollment of individuals between 2006 and 2010 across 22 different assessment centers throughout the United Kingdom. The tracking of participants is still ongoing. Within the UKB dataset, metabolomics, proteomics and retinal optical coherence tomography data are available for a subset of individuals without any enrichment for specific diseases. Additionally, EHRs, questionnaire responses and other physical measures are available for almost everyone in the study. Furthermore, a variety of genotype information is available for nearly the entire cohort, including whole-genome sequencing, whole-exome sequencing, genotyping array data as well as imputed genotypes from the genotyping array<sup>44</sup>. Because only the latter two are available for download, and are sufficient for polygenic risk score calculation as performed here, we used the imputed genotypes in the present study. Participants visited the assessment center up to four times for additional and repeat measurements and completed additional online follow-up questionnaires.

In the present study, we restricted the analyses to data obtained from the initial assessment, including the blood draw, for obtaining the metabolomics data and the retinal imaging as well as physical measures. This restricts the study population to 33,521 individuals for whom all of these modalities are available. We have a clear study start point for each individual with the date of their initial assessment center visit. The study population has a mean age of 57 years, is 54% female and is censored at age 69 years on average; 4.7% experienced an incident myocardial infarction; and 8.1% have prevalent type 2 diabetes. The study population comes from six of the 22 assessment centers due to the retinal imaging being performed only at those.

**Data collection.** For the myocardial infarction endpoint definition, we relied on the first occurrence data available in the UKB, which compiles the first date that each diagnosis was recorded for a participant in a hospital in ICD-10 nomenclature. Subsequently, we mapped these data to phecodes and focused on phecode 404.1 for myocardial infarction.

The Framingham Risk Score was developed on data from 8,491 participants in the Framingham Heart Study to assess general cardiovascular risk<sup>77</sup>. It includes easily obtainable predictors and is, therefore, easily applicable in clinical practice, although newer and more specific risk scores exist and might be used more frequently. It includes age, sex, smoking behavior, blood pressure, total and low-density lipoprotein cholesterol as well as information on insulin, antihypertensive and cholesterol-lowering medications, all of which are routinely collected in the UKB and used in this study as the Framingham feature set.

The metabolomics data used in this study were obtained using proton NMR spectroscopy, a low-cost method with relatively low batch effects. It covers established clinical predictors, such as albumin and cholesterol, as well as a range of lipids, amino acids and carbohydrate-related metabolites.

The retinal optical coherence tomography-derived features were returned by researchers to the UKB<sup>75,76</sup>. They used the available scans and determined the macular volume, macular thickness, retinal pigment epithelium thickness, disc diameter, cup-to-disk ratio across

different regions as well as the thickness between the inner nuclear layer and external limiting membrane, inner and outer photoreceptor segments and the retinal pigment epithelium across different regions. Furthermore, they determined a wide range of quality metrics for each scan, including the image quality score, minimum motion correlation and inner limiting membrane (ILM) indicator.

**Data analysis.** After exporting the data from the UKB, all timepoints were transformed into participant age entries. Only participants without prevalent myocardial infarction (relative to the first assessment center visit at which all data were collected) were included.

The data were pre-processed for retinal imaging and metabolomics subsets separately, to enable a clear analysis of missing data and allow for the  $k$ -nearest neighbors–based imputation ( $k = 20$ ) of missing values when less than 10% were missing for a given participant. Otherwise, participants were dropped from the analyses. The imputed genotypes and Framingham analyses were available for almost every participant and, therefore, not imputed. Individuals without them were, instead, dropped from the analyses. Because genetic risk modeling poses entirely different methodological and computational challenges, we applied a published polygenic risk score for coronary heart disease using 6.6 million variants<sup>73</sup>. This was computed using the plink2 score option on the imputed genotypes available in the UKB.

UMAP embeddings were computed using default parameters on the full feature sets with ehrapy's *umap* function. For all analyses, the same time-to-event and event-indicator columns were used. The event indicator is a Boolean variable indicating whether a myocardial infarction was observed for a study participant. The time to event is defined as the timespan between the start of the study, in this case the date of the first assessment center visit. Otherwise, it is the timespan from the start of the study to the start of censoring; in this case, this is set to the last date for which EHRs were available, unless a participant died, in which case the date of death is the start of censoring. Kaplan–Meier curves and Cox proportional hazards models were fit using ehrapy's survival analysis module and the lifelines<sup>124</sup> package's Cox-PHitter function with default parameters. For Cox proportional hazards models with multiple feature sets, individually imputed and quality-controlled feature sets were concatenated, and the model was fit on the resulting matrix. Models were evaluated using the C-index<sup>127</sup> as a metric. It can be seen as an extension of the common area under the receiver operator characteristic score to time-to-event datasets, in which events are not observed for every sample and which ranges from 0.0 (entirely false) over 0.5 (random) to 1.0 (entirely correct). CIs for the C-index were computed based on bootstrapping by sampling 1,000 times with replacement from all computed partial hazards and computing the C-index over each of these samples. The percentiles at 2.5% and 97.5% then give the upper and lower confidence bound for the 95% CIs.

In all UKB analyses, the unit of study for a statistical test or predictive model is always an individual study participant.

The generalizability of the analysis is limited as the UK Biobank cohort may not represent the general population, with potential selection biases and underrepresentation of the different demographic groups. Additionally, by restricting analysis to initial assessment data and censoring based on the last available EHR or date of death, our analysis does not account for longitudinal changes and can introduce follow-up bias, especially if participants lost to follow-up have different risk profiles.

**In-depth quality control of retina-derived features.** A UMAP plot of the retina-derived features indicating the assessment centers shows a cluster of samples that lie somewhat outside the general population and mostly attended the Birmingham assessment center (Fig. 5b). To further investigate this, we performed Leiden

clustering of resolution 0.3 (Extended Data Fig. 9a) and isolated this group in cluster 5. When comparing cluster 5 to the rest of the population in the retina-derived feature space, we noticed that many individuals in cluster 5 showed overall retinal pigment epithelium (RPE) thickness measures substantially elevated over the rest of the population in both eyes (Extended Data Fig. 9b), which is mostly a feature of this cluster (Extended Data Fig. 9c). To investigate potential confounding, we computed ratios between cluster 5 and the rest of the population over the 'obs' DataFrame containing the Framingham features, diabetes-related phecodes and genetic principal components. Out of the top and bottom five highest ratios observed, six are in genetic principal components, which are commonly used to represent genetic ancestry in a continuous space (Extended Data Fig. 9d). Additionally, diagnoses for type 1 and type 2 diabetes and antihypertensive use are enriched in cluster 5. Further investigating the ancestry, we computed log ratios for self-reported ancestries and absolute counts, which showed no robust enrichment and depletion effects.

A closer look at three quality control measures of the imaging pipeline revealed that cluster 5 was an outlier in terms of either image quality (Extended Data Fig. 9e) or minimum motion correlation (Extended Data Fig. 9f) and the ILM indicator (Extended Data Fig. 9g), all of which can be indicative of artifacts in image acquisition and downstream processing<sup>128</sup>. Subsequently, we excluded 301 individuals from cluster 5 from all analyses.

### COVID-19 chest-x-ray fate determination

**Dataset overview.** We used the public BrixIA COVID-19 dataset, which contains 192 chest x-ray images annotated with BrixIA scores<sup>82</sup>. Hereby, six regions were annotated by a senior radiologist with more than 20 years of experience and a junior radiologist with a disease severity score ranging from 0 to 3. A global score was determined as the sum of all of these regions and, therefore, ranges from 0 to 18 (S-Global). S-Global scores of 0 were classified as normal. Images that only had severity values up to 1 in all six regions were classified as mild. Images with severity values greater than or equal to 2, but a S-Global score of less than 7, were classified as moderate. All images that contained at least one 3 in any of the six regions with a S-Global score between 7 and 10 were classified as severe, and all remaining images with S-Global scores greater than 10 with at least one 3 were labeled critical. The dataset and instructions to download the images can be found at <https://github.com/ieee8023/covid-chestxray-dataset>.

**Dataset extraction and analysis.** We first resized all images to  $224 \times 224$ . Afterwards, the images underwent a random affine transformation that involved rotation, translation and scaling. The rotation angle was randomly selected from a range of  $-45^\circ$  to  $45^\circ$ . The images were also subject to horizontal and vertical translation, with the maximum translation being 15% of the image size in either direction. Additionally, the images were scaled by a factor ranging from 0.85 to 1.15. The purpose of applying these transformations was to enhance the dataset and introduce variations, ultimately improving the robustness and generalization of the model.

To generate embeddings, we used a pre-trained DenseNet model with weights *densenet121-res224-all* of TorchXRayVision<sup>129</sup>. A DenseNet is a convolutional neural network that makes use of dense connections between layers (Dense Blocks) where all layers (with matching feature map sizes) directly connect with each other. To maintain a feed-forward nature, every layer in the DenseNet architecture receives supplementary inputs from all preceding layers and transmits its own feature maps to all subsequent layers. The model was trained on the *nih-pc-chex-mimic\_ch-google-openi-rsna* dataset<sup>130</sup>.

Next, we calculated 50 principal components on the feature representation of the DenseNet model of all images using ehrapy's *pca* function. The principal component representation served as

input for a nearest neighbors graph calculation using ehrapy's *neighbors* function. This graph served as the basis for the calculation of a UMAP embedding with three components that was finally visualized using ehrapy.

We randomly picked a root in the group of images that was labeled 'Normal'. First, we calculated so-called pseudotime by fitting a trajectory through the calculated UMAP space using diffusion maps as implemented in ehrapy's *dpt* function<sup>57</sup>. Each image's pseudotime value represents its estimated position along this trajectory, serving as a proxy for its severity stage relative to others in the dataset. To determine fates, we employed CellRank<sup>38,59</sup> with the *PseudotimeKernel*. This kernel computes transition probabilities for patient visits based on the connectivity of the *k*-nearest neighbors graph and the pseudotime values of patient visits, which resembles their progression through a process. Directionality is infused in the nearest neighbors graph in this process where the kernel either removes or downweights edges in the graph that contradict the directional flow of increasing pseudotime, thereby refining the graph to better reflect the developmental trajectory. We computed the transition matrix with a soft threshold scheme (Parameter of the *PseudotimeKernel*), which downweights edges that point against the direction of increasing pseudotime. Finally, we calculated a projection on top of the UMAP embedding with CellRank using the *plot\_projection* function of the *PseudotimeKernel* that we subsequently plotted.

This analysis is limited by the small dataset of 192 chest x-ray images, which may affect the model's generalizability and robustness. Annotation subjectivity from radiologists can further introduce variability in severity scores. Additionally, the random selection of a root from 'Normal' images can introduce bias in pseudotime calculations and subsequent analyses.

### Diabetes 130-US hospitals analysis

**Study population.** We used data from the Diabetes 130-US hospitals dataset that were collected between 1999 and 2008. It contains clinical care information at 130 hospitals and integrated delivery networks. The extracted database information pertains to hospital admissions specifically for patients diagnosed with diabetes. These encounters required a hospital stay ranging from 1 d to 14 d, during which both laboratory tests and medications were administered. The selection criteria focused exclusively on inpatient encounters with these defined characteristics. More specifically, we used a version that was curated by the Fairlearn team where the target variable 'readmitted' was binarized and a few features renamed or binned ([https://fairlearn.org/main/user\\_guide/datasets/diabetes\\_hospital\\_data.html](https://fairlearn.org/main/user_guide/datasets/diabetes_hospital_data.html)). The dataset contains 101,877 patient visits and 25 features. The dataset predominantly consists of White patients (74.8%), followed by African Americans (18.9%), with other racial groups, such as Hispanic, Asian and Unknown categories, comprising smaller percentages. Females make up a slight majority in the data at 53.8%, with males accounting for 46.2% and a negligible number of entries listed as unknown or invalid. A substantial majority of the patients are over 60 years of age (67.4%), whereas those aged 30–60 years represent 30.2%, and those 30 years or younger constitute just 2.5%.

**Data analysis.** All of the following descriptions start by loading the Fairlearn version of the Diabetes 130-US hospitals dataset using ehrapy's dataloader as an AnnData object.

**Selection and filtering bias.** An overview of sensitive variables was generated using tableone. Subsequently, ehrapy's *CohortTracker* was used to track the age, gender and race variables. The cohort was filtered for all Medicare recipients and subsequently plotted.

**Surveillance bias.** We plotted the HbA1c measurement ratios using ehrapy's *catplot*.

**Missing data and imputation bias.** MCAR-type missing data for the number of medications variable ('num\_medications') were introduced by randomly setting 30% of the variables to be missing using Numpy's *choice* function. We tested that the data are MCAR by applying ehrapy's implementation of Little's MCAR test, which returned a non-significant *P* value of 0.71. MAR data for the number of medications variable ('num\_medications') were introduced by scaling the 'time\_in\_hospital' variable to have a mean of 0 and a standard deviation of 1, adjusting these values by multiplying by 1.2 and subtracting 0.6 to influence overall missingness rate, and then using these values to generate MAR data in the 'num\_medications' variable via a logistic transformation and binomial sampling. We verified that the newly introduced missing values are not MCAR with respect to the 'time\_in\_hospital' variable by applying ehrapy's implementation of Little's test, which was significant ( $0.01 \times 10^{-2}$ ). The missing data were imputed using ehrapy's mean imputation and MissForest implementation.

**Algorithmic bias.** Variables 'race', 'gender', 'age', 'readmitted', 'readmit\_binary' and 'discharge\_disposition\_id' were moved to the 'obs' slot of the AnnData object to ensure that they were not used for model training. We built a binary label 'readmit\_30\_days' indicating whether a patient had been readmitted in fewer than 30 d. Next, we combined the 'Asian' and 'Hispanic' categories into a single 'Other' category within the 'race' column of our AnnData object and then filtered out and discarded any samples labeled as 'Unknown/Invalid' under the 'gender' column and subsequently moved the 'gender' data to the variable matrix *X* of the AnnData object. All categorical variables got encoded. The data were split into train and test groups with a test size of 50%. The data were scaled, and a logistic regression model was trained using scikit-learn, which was also used to determine the balanced accuracy score. Fairlearn's *MetricFrame* function was used to inspect the target model performance against the sensitive variable 'race'. We subsequently fit Fairlearn's *ThresholdOptimizer* using the logistic regression estimator with *balanced\_accuracy\_score* as the target object. The algorithmic demonstration of Fairlearn's abilities on this dataset is shown here: [https://github.com/fairlearn/talks/tree/main/2021\\_scipy\\_tutorial](https://github.com/fairlearn/talks/tree/main/2021_scipy_tutorial).

**Normalization bias.** We one-hot encoded all categorical variables with ehrapy using the *encode* function. We applied ehrapy's implementation of scaling normalization with and without the 'Age group' variable as group key to scale the data jointly and separately using ehrapy's *scale\_norm* function.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Physionet provides access to the PIC database<sup>43</sup> at <https://physionet.org/content/picdb/1.1.0> for credentialed users. The BrixIA images<sup>82</sup> are available at <https://github.com/BrixIA/Brixia-score-COVID-19>. The data used in this study were obtained from the UK Biobank<sup>44</sup> (<https://www.ukbiobank.ac.uk/>). Access to the UK Biobank resource was granted under application number 49966. The data are available to researchers upon application to the UK Biobank in accordance with their data access policies and procedures. The Diabetes 130-US Hospitals dataset is available at <https://archive.ics.uci.edu/dataset/296/diabetes+130-u+s+hospitals+for+years+1999-2008>.

### Code availability

The ehrapy source code is available at <https://github.com/theislabs/ehrapy> under an Apache 2.0 license. Further documentation, tutorials and examples are available at <https://ehrapy.readthedocs.io>. We are actively developing the software and invite contributions from the community.



Jupyter notebooks to reproduce our analysis and figures, including Conda environments that specify all versions, are available at <https://github.com/theislabs/ehrapy-reproducibility>.

## References

101. Hunter, J. D. Matplotlib: a 2D graphics environment. *Comput. Sci. Eng.* **9**, 90–95 (2007).
102. Waskom, M. seaborn: statistical data visualization. *J. Open Source Softw.* **6**, 3021 (2021).
103. Harris, C. R. et al. Array programming with NumPy. *Nature* **585**, 357–362 (2020).
104. Lam, S. K., Pitrou, A. & Seibert, S. Numba: a LLVM-based Python JIT compiler. In *Proc. of the Second Workshop on the LLVM Compiler Infrastructure in HPC*. <https://doi.org/10.1145/2833157.2833162> (Association for Computing Machinery, 2015).
105. Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nat. Methods* **17**, 261–272 (2020).
106. McKinney, W. Data structures for statistical computing in Python. In *Proc. of the 9th Python in Science Conference* (eds van der Walt, S. & Millman, J.). <https://doi.org/10.25080/majora-92bf1922-00a> (SciPy, 2010).
107. Boulanger, A. Open-source versus proprietary software: is one more reliable and secure than the other? *IBM Syst. J.* **44**, 239–248 (2005).
108. Rocklin, M. Dask: parallel computation with blocked algorithms and task scheduling. In *Proc. of the 14th Python in Science Conference*. <https://doi.org/10.25080/majora-7b98e3ed-013> (SciPy, 2015).
109. Pivarski, J. et al. Awkward Array. <https://doi.org/10.5281/ZENODO.4341376>
110. Collette, A. *Python and HDF5: Unlocking Scientific Data* (O'Reilly Media, Inc., 2013).
111. Miles, A. et al. zarr-developers/zarr-python: v2.13.6. <https://doi.org/10.5281/zenodo.7541518> (2023).
112. The pandas development team. pandas-dev/pandas: Pandas. <https://doi.org/10.5281/ZENODO.3509134> (2024).
113. Weberpals, J. et al. Deep learning-based propensity scores for confounding control in comparative effectiveness research: a large-scale, real-world data study. *Epidemiology* **32**, 378–388 (2021).
114. Rosenthal, J. et al. Building tools for machine learning and artificial intelligence in cancer research: best practices and a case study with the PathML toolkit for computational pathology. *Mol. Cancer Res.* **20**, 202–206 (2022).
115. Gayoso, A. et al. A Python library for probabilistic analysis of single-cell omics data. *Nat. Biotechnol.* **40**, 163–166 (2022).
116. Paszke, A. et al. PyTorch: an imperative style, high-performance deep learning library. In *Advances in Neural Information Processing Systems* **32** (eds Wallach, H. et al.). 8024–8035 (Curran Associates, 2019).
117. Frostig, R., Johnson, M. & Leary, C. Compiling machine learning programs via high-level tracing. <https://cs.stanford.edu/~rfrostig/pubs/jax-mlsys2018.pdf> (2018).
118. Moor, M. et al. Foundation models for generalist medical artificial intelligence. *Nature* **616**, 259–265 (2023).
119. Kraljevic, Z. et al. Multi-domain clinical natural language processing with MedCAT: the Medical Concept Annotation Toolkit. *Artif. Intell. Med.* **117**, 102083 (2021).
120. Pollard, T. J., Johnson, A. E. W., Raffa, J. D. & Mark, R. G. An open source Python package for producing summary statistics for research papers. *JAMIA Open* **1**, 26–31 (2018).
121. Ellen, J. G. et al. Participant flow diagrams for health equity in AI. *J. Biomed. Inform.* **152**, 104631 (2024).
122. Schouten, R. M. & Vink, G. The dance of the mechanisms: how observed information influences the validity of missingness assumptions. *Sociol. Methods Res.* **50**, 1243–1258 (2021).
123. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. *Biostatistics* **8**, 118–127 (2007).
124. Davidson-Pilon, C. lifelines: survival analysis in Python. *J. Open Source Softw.* **4**, 1317 (2019).
125. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. R. Stat. Soc. Ser. B Stat. Methodol.* **57**, 289–300 (1995).
126. Wishart, D. S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res.* **34**, D668–D672 (2006).
127. Harrell, F. E. Jr, Califf, R. M., Pryor, D. B., Lee, K. L. & Rosati, R. A. Evaluating the yield of medical tests. *JAMA* **247**, 2543–2546 (1982).
128. Currant, H. et al. Genetic variation affects morphological retinal phenotypes extracted from UK Biobank optical coherence tomography images. *PLoS Genet.* **17**, e1009497 (2021).
129. Cohen, J. P. et al. TorchXRyVision: a library of chest X-ray datasets and models. In *Proc. of the 5th International Conference on Medical Imaging with Deep Learning* (eds Konukoglu, E. et al.). **172**, 231–249 (PMLR, 2022).
130. Cohen, J. P., Hashir, M., Brooks, R. & Bertrand, H. On the limits of cross-domain generalization in automated X-ray prediction. In *Proceedings of Machine Learning Research*, Vol. 121 (eds Arbel, T. et al.) 136–155 (PMLR, 2020).

## Acknowledgements

We thank M. Ansari who designed the ehrapy logo. The authors thank F. A. Wolf, M. Lücken, J. Steinfeldt, B. Wild, G. Rätsch and D. Shung for feedback on the project. We further thank L. Halle, Y. Ji, M. Lücken and R. K. Rubens for constructive comments on the paper. We thank F. Hashemi for her help in implementing the survival analysis module. This research was conducted using data from the UK Biobank, a major biomedical database (<https://www.ukbiobank.ac.uk>), under application number 49966. This work was supported by the German Center for Lung Research (DZL), the Helmholtz Association and the CRC/TRR 359 Perinatal Development of Immune Cell Topology (PILOT). N.H. and F.J.T. acknowledge support from the German Federal Ministry of Education and Research (BMBF) (LODE, 031L0210A), co-funded by the European Union (ERC, DeepCell, 101054957). A.N. is supported by the Konrad Zuse School of Excellence in Learning and Intelligent Systems (ELIZA) through the DAAD program Konrad Zuse Schools of Excellence in Artificial Intelligence, sponsored by the Federal Ministry of Education and Research. This work was also supported by the Chan Zuckerberg Initiative (CZIF2022-007488; Human Cell Atlas Data Ecosystem).

## Author contributions

L. Heumos and F.J.T. conceived the study. L. Heumos, P.E., X.Z., E.R., L.M., A.N., L.Z., V.S., T.T., L. Hetzel, N.H., R.K. and I.V. implemented ehrapy. L. Heumos, P.E., N.L., L.S., T.T. and A.H. analyzed the PIC database. J.U.z.B. and L. Heumos analyzed the UK Biobank database. X.Z. and L. Heumos analyzed the COVID-19 chest x-ray dataset. L. Heumos, P.E. and J.U.z.B. wrote the paper. F.J.T., A.H., H.B.S. and R.E. supervised the work. All authors read, corrected and approved the final paper.

## Funding

Open access funding provided by Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH).

## Competing interests

L. Heumos is an employee of LaminLabs. F.J.T. consults for Immunai Inc., Singularity Bio B.V., CytoReason Ltd. and Omniscio Ltd. and

has ownership interest in Dermagnostix GmbH and Cellarity. The remaining authors declare no competing interests.

## Additional information

















**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-024-03214-0>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-024-03214-0>.

**Correspondence and requests for materials** should be addressed to Fabian J. Theis.

**Peer review information** *Nature Medicine* thanks Leo Anthony Celi and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary handling editor: Lorenzo Righetto, in collaboration with the *Nature Medicine* team.


**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

Paediatric Intensive Care database			
Table	Description	Coverage Rate	Categorical values
 CHARTEVENTS	All charted observations for the patients from the hospital database	79,7%	No
 D_LABITEMS	Dictionary of local codes related to laboratory tests	Not applicable	Yes
 D_ICD_DIAGNOSES	Dictionary of ICD-10 codes and ICD-O-3 relating to diagnoses	Not applicable	Yes
 D_ITEMS	Dictionary of local codes not related to laboratory tests	Not applicable	Yes
 DIAGNOSES_ICD	Hospital assigned diagnoses, coded using Chinese ICD-10 and ICD-O-3	99,4%	Yes
 LABEVENTS	Laboratory measurements for patients from the hospital database	93,9%	Yes
 MICROBIOLOGYEVENTS	Microbiology culture results and antibiotic sensitivities from the hospital database	89,7%	Yes
 PRESCRIPTIONS	Medications ordered for a given patient	51,5%	Yes
 ICUSTAYS	ICU stay metadata such as the type of care unit	100%	Yes
 PATIENTS	Patient metadata such as age, gender, survival	100%	Yes
 ADMISSIONS	Every unique hospitalization for each patient in the database	100%	Yes
 OUTPUTEVENTS	Output information for patients from the hospital database	11,7%	No
 SURGERY_VITAL_SIGNS	Vital signs recorded every five minutes during surgeries	24,7%	No
 INPUTEVENTS	Daily calculated fluid input data for each ICU patient	41,1%	No
 OR_EXAM_REPORTS	Contains all exams performed during the patient's stay	91,9%	Yes
 EMR_SYMPTOMS	Structured symptoms extracted from notes, including nursing and physician notes	6,7%	Yes

**Extended Data Fig. 1 | Overview of the paediatric intensive care database (PIC).** The database consists of several tables corresponding to several data modalities and measurement types. All tables colored in green were selected for


analysis and all tables in blue were discarded based on coverage rate. Despite the high coverage rate, we discarded the ‘OR\_EXAM\_REPORTS’ table because of the lack of detail in the exam reports.






**Extended Data Fig. 2 | Preprocessing of the Paediatric Intensive Care (PIC) dataset with ehrapy. (a)** Heterogeneous data of the PIC database was stored in 'data' (matrix that is used for computations) and 'observations' (metadata per patient visit). During quality control, further annotations are added to the

'variables' (metadata per feature) slot. **(b)** Preprocessing steps of the PIC dataset. **(c)** Example of the function calls in the data analysis pipeline that resembles the preprocessing steps in (B) using ehrapy.




**Extended Data Fig. 3 | Missing data distribution for the 'youths' group of the PIC dataset.** The x-axis represents the percentage of missing values in each feature. The y-axis reflects the number of features in each bin with text labels representing the names of the individual features.




**Extended Data Fig. 4 | Patient selection during analysis of the PIC dataset.** Filtering for the pneumonia cohort of the youths filters out care units except for the general intensive care unit and the pediatric intensive care unit.






**Extended Data Fig. 5 | Feature rankings of stratified patient groups.** Scores reflect the z-score underlying the p-value per measurement for each group. Higher scores (above 0) reflect overrepresentation of the measurement compared to all other groups and vice versa. **(a)** By clinical chemistry. **(b)** By liver markers. **(c)** By medication type. **(d)** By infection markers.




**Extended Data Fig. 6 | Liver marker value progression for the ‘youths’ group and Kaplan-Meier curves.** (a) Viral and severe pneumonia with co-infection groups display enriched gamma-glutamyl transferase levels in blood serum. (b) Aspartate transferase (AST) and Alanine transaminase (ALT) levels are enriched

for severe pneumonia with co-infection during early ICU stay. (c) and (d) Kaplan-Meier curves for ALT and AST demonstrate lower survivability for children with measurements outside the norm.




**Extended Data Fig. 7 | Overview of medication categories used for causal inference. (a)** Feature engineering process to group administered medications into medication categories using drugbank. **(b)** Number of medications per medication category. **(c)** Number of patients that received (dark blue) and did not receive specific medication categories (light blue).





**Extended Data Fig. 8 | UK-Biobank data overview and quality control across modalities.** (a) UMAP plot of the metabolomics data demonstrating a clear gradient with respect to age at sampling, and (b) type 2 diabetes prevalence. (c) Analogously, the features derived from retinal imaging show a less pronounced age gradient, and (d) type 2 diabetes prevalence gradient. (e) Stratifying myocardial infarction risk by the type 2 diabetes comorbidity confirms vastly increased risk with a prior type 2 (T2D) diabetes diagnosis.


Kaplan-Meier estimators with 95 % confidence intervals are shown. (f) Similarly, the polygenic risk score for coronary heart disease used in this work substantially enriches myocardial infarction risk in its top 5% percentile. Kaplan-Meier estimators with 95 % confidence intervals are shown. (g) UMAP visualization of the metabolomics features colored by the assessment center shows no discernable biases. (A-G)  $n = 29,216$ .



**Extended Data Fig. 9 | UK-Biobank retina derived feature quality control.**

(a) Leiden Clustering of retina derived feature space. (b) Comparison of 'overall retinal pigment epithelium (RPE) thickness' values between cluster 5 ( $n = 301$ ) and the rest of the population ( $n = 28,915$ ). (c) RPE thickness in the right eye outliers on the UMAP largely corresponds to cluster 5. (d) Log ratio of top and

bottom 5 fields in obs dataframe between cluster 5 and the rest of the population. (e) Image Quality of the optical coherence tomography scan as reported in the UKB. (f) Minimum motion correlation quality control indicator. (g) Inner limiting membrane (ILM) quality control indicator. (D-G) Data are shown for the right eye only, comparable results for the left eye are omitted. (A-G)  $n = 29,216$ .



Extended Data Fig. 10 | See next page for caption.

**Extended Data Fig. 10 | Bias detection and mitigation study on the Diabetes 130-US hospitals dataset (n = 101,766 hospital visits, one patient can have multiple visits).** (a) Filtering to the visits of Medicare recipients results in an increase of Caucasians. (b) Proportion of visits where Hb1Ac measurements are recorded, stratified by admission type. Adjusted P values were calculated with Chi squared tests and Bonferroni correction (Adjusted P values: Emergency vs Referral 3.3E-131, Emergency vs Other 1.4E-101, Referral vs Other 1.6E-4.) (c) Normalizing feature distributions jointly vs. separately can mask distribution differences. (d) Imputing the number of medications for visits. Onto the complete data (blue), MCAR (30% missing data) and MAR (38% missing data) were introduced (orange), with the MAR mechanism depending on the time in hospital. Mean imputation (green) can reduce the variance of the distribution

under MCAR and MAR mechanisms, and bias the center of the distribution under an MAR mechanism. Multiple imputation, such as MissForest imputation can impute meaningfully even in MAR cases, when having access to variables involved in the MAR mechanism. Each boxplot represents the IQR of the data, with the horizontal line inside the box indicating the median value. The left and right bounds of the box represent the first and third quartiles, respectively. The 'whiskers' extend to the minimum and maximum values within 1.5 times the IQR from the lower and upper quartiles, respectively. (e) Predicting the early readmission within 30 days after release on a per-stay level. Balanced accuracy can mask differences in selection and false negative rate between sensitive groups.



Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- |                          |  |
|--------------------------|--|
| n/a                      | Confirmed  |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The exact sample size ( <i>n</i> ) for each experimental group/condition, given as a discrete number and unit of measurement   |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly  |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> The statistical test(s) used AND whether they are one- or two-sided<br><i>Only common tests should be described solely by name; describe more complex techniques in the Methods section.</i>   |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A description of all covariates tested   |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons  |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted<br><i>Give P values as exact values whenever suitable.</i>                     |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings   |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes   |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i> ), indicating how they were calculated   |

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection	<p>No software was used to collect data. Physionet provides access to the PIC database at <a href="https://physionet.org/content/picdb/1.1.0">https://physionet.org/content/picdb/1.1.0</a> for credentialed users. The BrixIA images are available at <a href="https://github.com/BrixIA/Brixia-score-COVID-19">https://github.com/BrixIA/Brixia-score-COVID-19</a>. The diabetic retinopathy dataset is available at <a href="https://www.kaggle.com/c/diabetic-retinopathy-detection/data">https://www.kaggle.com/c/diabetic-retinopathy-detection/data</a>. The UK Biobank data were obtained from the <a href="http://www.ukbiobank.ac.uk">www.ukbiobank.ac.uk</a>. Access to the UK Biobank resource was granted under application number 49966. The data are available to researchers upon application to the UK Biobank in accordance with their data access policies and procedures. The Diabetes 130-US Hospitals dataset is available at <a href="https://archive.ics.uci.edu/dataset/296/diabetes+130-us+hospitals+for+years+1999-2008">https://archive.ics.uci.edu/dataset/296/diabetes+130-us+hospitals+for+years+1999-2008</a>.</p> <p>No software was used to collect data. Physionet provides access to the PIC database at <a href="https://physionet.org/content/picdb/1.1.0">https://physionet.org/content/picdb/1.1.0</a> for credentialed users. The BrixIA images are available at <a href="https://github.com/BrixIA/Brixia-score-COVID-19">https://github.com/BrixIA/Brixia-score-COVID-19</a>. The diabetic retinopathy dataset is available at <a href="https://www.kaggle.com/c/diabetic-retinopathy-detection/data">https://www.kaggle.com/c/diabetic-retinopathy-detection/data</a>. The UK Biobank data were obtained from the <a href="http://www.ukbiobank.ac.uk">www.ukbiobank.ac.uk</a>. Access to the UK Biobank resource was granted under application number 49966. The data are available to researchers upon application to the UK Biobank in accordance with their data access policies and procedures. The Diabetes 130-US Hospitals dataset is available at <a href="https://archive.ics.uci.edu/dataset/296/diabetes+130-us+hospitals+for+years+1999-2008">https://archive.ics.uci.edu/dataset/296/diabetes+130-us+hospitals+for+years+1999-2008</a>.</p> <p>No software was used to collect data. Physionet provides access to the PIC database at <a href="https://physionet.org/content/picdb/1.1.0">https://physionet.org/content/picdb/1.1.0</a> for credentialed users. The BrixIA images are available at <a href="https://github.com/BrixIA/Brixia-score-COVID-19">https://github.com/BrixIA/Brixia-score-COVID-19</a>. The diabetic retinopathy dataset is available at <a href="https://www.kaggle.com/c/diabetic-retinopathy-detection/data">https://www.kaggle.com/c/diabetic-retinopathy-detection/data</a>. The UK Biobank data were obtained from the <a href="http://www.ukbiobank.ac.uk">www.ukbiobank.ac.uk</a>. Access to the UK Biobank resource was granted under application number 49966. The data are available to researchers upon application to the UK Biobank in accordance with their data access policies and procedures. The Diabetes 130-US Hospitals dataset is available at <a href="https://archive.ics.uci.edu/dataset/296/diabetes+130-us+hospitals+for+years+1999-2008">https://archive.ics.uci.edu/dataset/296/diabetes+130-us+hospitals+for+years+1999-2008</a>.</p>
Data analysis	<p>Python 3.11 ehrapy 0.8.0</p>

anndata 0.10.3  
 cellrank 2.0.4  
 Dowhy 0.11  
 Fairlearn 0.10.0  
 pandas 2.2.2  
 scanpy 1.10.1  
 seaborn 0.13.2  
 tableone 0.8.0

All code of the newly developed software solution ehrapy that is essential for the analysis is available on <https://github.com/theislabs/ehrapy> and <https://github.com/theislabs/ehrapy-tutorials>.

Python 3.11  
 ehrapy 0.8.0  
 anndata 0.10.3  
 cellrank 2.0.4  
 Dowhy 0.11  
 Fairlearn 0.10.0  
 pandas 2.2.2  
 scanpy 1.10.1  
 seaborn 0.13.2  
 tableone 0.8.0

All code of the newly developed software solution ehrapy that is essential for the analysis is available on <https://github.com/theislabs/ehrapy> and <https://github.com/theislabs/ehrapy-tutorials>.

Python 3.11  
 ehrapy 0.8.0  
 anndata 0.10.3  
 cellrank 2.0.4  
 Dowhy 0.11  
 Fairlearn 0.10.0  
 pandas 2.2.2  
 scanpy 1.10.1  
 seaborn 0.13.2  
 tableone 0.8.0

All code of the newly developed software solution ehrapy that is essential for the analysis is available on <https://github.com/theislabs/ehrapy> and <https://github.com/theislabs/ehrapy-tutorials>.

Python 3.11  
 ehrapy 0.8.0  
 anndata 0.10.3  
 cellrank 2.0.4  
 Dowhy 0.11  
 Fairlearn 0.10.0  
 pandas 2.2.2  
 scanpy 1.10.1  
 seaborn 0.13.2  
 tableone 0.8.0

All code of the newly developed software solution ehrapy that is essential for the analysis is available on <https://github.com/theislabs/ehrapy> and <https://github.com/theislabs/ehrapy-tutorials>.

Python 3.11  
 ehrapy 0.8.0  
 anndata 0.10.3  
 cellrank 2.0.4  
 Dowhy 0.11  
 Fairlearn 0.10.0  
 pandas 2.2.2  
 scanpy 1.10.1  
 seaborn 0.13.2  
 tableone 0.8.0

All code of the newly developed software solution ehrapy that is essential for the analysis is available on <https://github.com/theislabs/ehrapy> and <https://github.com/theislabs/ehrapy-tutorials>.

Python 3.11  
 ehrapy 0.8.0  
 anndata 0.10.3  
 cellrank 2.0.4  
 Dowhy 0.11  
 Fairlearn 0.10.0  
 pandas 2.2.2  
 scanpy 1.10.1  
 seaborn 0.13.2  
 tableone 0.8.0

All code of the newly developed software solution ehrapy that is essential for the analysis is available on <https://github.com/theislabs/ehrapy> and <https://github.com/theislabs/ehrapy-tutorials>.

Python 3.11  
 ehrapy 0.8.0  
 anndata 0.10.3  
 cellrank 2.0.4  
 Dowhy 0.11  
 Fairlearn 0.10.0

pandas 2.2.2  
scanpy 1.10.1  
seaborn 0.13.2  
tableone 0.8.0

All code of the newly developed software solution ehrapy that is essential for the analysis is available on <https://github.com/theislabs/ehrapy> and <https://github.com/theislabs/ehrapy-tutorials>.

Python 3.11 ehrapy 0.8.0 anndata 0.10.3 cellrank 2.0.4 Dowhy 0.11 Fairlearn 0.10.0 pandas 2.2.2 scanpy 1.10.1 seaborn 0.13.2 tableone 0.8.0  
All code of the newly developed software solution ehrapy that is essential for the analysis is available on <https://github.com/theislabs/ehrapy> and <https://github.com/theislabs/ehrapy-tutorials>.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Physionet provides access to the PIC database<sup>43</sup> at <https://physionet.org/content/picdb/1.1.0> for credentialed users. The BrixIA images<sup>82</sup> are available at <https://github.com/BrixIA/Brixia-score-COVID-19>. The data used in this study were obtained from the UK Biobank<sup>44</sup> ([www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk)). Access to the UK Biobank resource was granted under application number 49966. The data are available to researchers upon application to the UK Biobank in accordance with their data access policies and procedures. The Diabetes 130-US Hospitals dataset is available at <https://archive.ics.uci.edu/dataset/296/diabetes+130-us+hospitals+for+years+1999-2008>.

Physionet provides access to the PIC database<sup>43</sup> at <https://physionet.org/content/picdb/1.1.0> for credentialed users. The BrixIA images<sup>82</sup> are available at <https://github.com/BrixIA/Brixia-score-COVID-19>. The data used in this study were obtained from the UK Biobank<sup>44</sup> ([www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk)). Access to the UK Biobank resource was granted under application number 49966. The data are available to researchers upon application to the UK Biobank in accordance with their data access policies and procedures. The Diabetes 130-US Hospitals dataset is available at <https://archive.ics.uci.edu/dataset/296/diabetes+130-us+hospitals+for+years+1999-2008>.

## Research involving human participants, their data, or biological material

Policy information about studies with [human participants or human data](#). See also policy information about [sex, gender \(identity/presentation\), and sexual orientation](#) and [race, ethnicity and racism](#).

### Reporting on sex and gender

When using the term sex or gender, we refer to biological sex in our study. Sex distributions of the respective cohorts that we analyzed can be found in the corresponding Methods sections.

### Reporting on race, ethnicity, or other socially relevant groupings

The respective ethnicity distributions of the respective cohorts that we analyzed can be found in the corresponding Methods sections.

### Population characteristics

We analyzed the Pediatric Intensive Care (PIC) database which records 13,499 hospital admissions involving 12,881 unique pediatric patients aged 0–18 years, between 2010 and 2018. A subset of these patients, 468 (3.6%), experienced multiple admissions. The average age at admission was 2.5 years, with the first to third quartile range from 0.1 to 3.3 years. Most of the patients (57.5%) were male. The mortality rate within the hospital was 7.1%. The average length of a hospital stay was 17.6 days, with the first to third quartile range from 7.0 to 21.0 days, and the average length of stay in the ICU was 9.3 days, with a range from 0.9 to 9.2 days. The neonatal ICU recorded the longest average stays at 21.6 days (Q1–Q3: 2.5–32.8), while the surgical ICU had the shortest at 2.3 days (Q1–Q3: 0.8–1.6). The most common categories of diagnoses at discharge were congenital malformations, deformations, and chromosomal abnormalities (25.4%, codes Q00–Q99), conditions originating in the perinatal period (14.1%, codes P00–P96), and respiratory system diseases (10.3%, codes J00–J99). More details on the cohort can be found in the original publication of the dataset in Zeng et al. Nature Scientific Data (2020). We further analyzed data from the UK Biobank cohort. It has data of enrolled individuals at 22 assessment centers throughout the United Kingdom from 2006 to 2010. For this analysis, the focus is on data collected during the initial assessment, which includes a blood draw for metabolomics data via NMR techniques, retinal imaging, and physical measurements. This selection criteria limits the dataset to 32,436 participants who had all these assessments. The study participants primarily come from six out of the 22 centers, reflecting the availability of retinal imaging at these locations. The cohort has an average age of 57 years, consists of 54% females, and has an average censoring age of 69. Regarding health outcomes, 4.7% of the participants have had a myocardial infarction, and 8.1% have been diagnosed with type 2 diabetes. We analyzed the public BrixIA COVID-19 Dataset which contains 192 chest X-ray images annotated with Brixia-scores. Hereby, 6 regions were annotated by radiologists with scores ranging from 0–3 (disease severity). 39 of the images were control and the remaining 153 images were annotated with COVID-19. Covariates such as age or sex are not reported in the original study by Signoroni et al. Medical Image Analysis (2021). The Diabetes 130-US hospitals dataset, collected between 1999 and 2008, consists of clinical care information from 130 hospitals and integrated delivery networks in the U.S., focusing on inpatient admissions of diabetic patients. These patients had hospital stays ranging from 1 to 14 days, where they underwent various laboratory tests and received medications. The dataset includes 101,877 patient visits and 25 features, following selection criteria that narrowed it down to inpatient encounters only. The fairlearn team curated a version of this dataset, binarizing the target variable "readmitted" and modifying some feature names and categories. The majority of patients are Caucasian (74.8%), followed by African Americans (18.9%), with other races making up smaller percentages. There is a slight female majority (53.8%), and most patients are over 60 years old (67.4%).

Recruitment

We did not recruit any patients. This is a retrospective study.

Ethics oversight

All used datasets have been published previously with consent of the respective participants and their ethics boards. We refer to the respective ethics statements of the corresponding publications.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences☐ Behavioural & social sciences☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

The data analyzed comprised 12,811 distinct pediatric patients of the Paediatric Intensive Care database, 32,426 individuals of the UK Biobank, 71518 patients of the Diabetes 130-US Hospitals dataset, and 192 chest X-ray images of the BrixIA dataset. We select these six datasets because they cover very different cohorts with different ethnic backgrounds, disease profiles, and number of study participants. We therefore deem the number of analyzed datasets sufficient to demonstrate the robust applicability of our framework ehrapy.

Data exclusions

Excluded individuals based on quality control criteria described in the manuscript.

Replication

e reproducible, we deposited the complete end-to-end analysis code on the associated reproducibility Github repository (<https://github.com/theislabs/ehrapy-reproducibility>) together with the used software package versions. Whenever performing Leiden clustering, we ensured that the obtained clusters and annotations were robust to several clustering resolutions. Our causal inference use-case was tested for replicability using refuters that challenge the causal model's assumptions. We applied the "placebo\_treatment\_refuter" to test if the treatment genuinely causes the observed effect by substituting it with a placebo. Meanwhile, "random\_common\_cause" and "add\_unobserved\_common\_cause" introduce hypothetical confounders to assess sensitivity to unknown variables. The "data\_subset\_refuter" verifies consistency by recalculating effects across various data subsets.

Randomization

To calculate confidence intervals for the C-index, we performed bootstrapping by randomly sampling 1000 times with replacement from all computed partial hazards and computing the C-index over each of these samples. To illustrate the potential for machine learning models to exhibit ethnic bias, we implemented balanced random undersampling to equalize the number of control and disease cases across different ethnic groups.

Blinding

This is a retrospective study, which utilizes pre-existing data where interventions and outcomes have already been recorded, hence blinding is unnecessary as it does not affect the results.

## Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).

Research sample

State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.

Sampling strategy

Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.

Data collection

Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.

Timing

Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.

Data exclusions

If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Non-participation

State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.



## Randomization

If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

## Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

## Study description

Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.

## Research sample

Describe the research sample (e.g. a group of tagged *Passer domesticus*, all *Stenocereus thurberi* within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.

## Sampling strategy

Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

## Data collection

Describe the data collection procedure, including who recorded the data and how.

## Timing and spatial scale

Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken

## Data exclusions

If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

## Reproducibility

Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.

## Randomization

Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.

## Blinding

Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.

Did the study involve field work? ☐ Yes ☐ No

## Field work, collection and transport

## Field conditions

Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).

## Location

State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).

## Access &amp; import/export

Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).

## Disturbance

Describe any disturbance caused by the study and how it was minimized.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials &amp; experimental systems

- n/a Involved in the study
- ☐ ☐ Antibodies
- ☐ ☐ Eukaryotic cell lines
- ☐ ☐ Palaeontology and archaeology
- ☐ ☐ Animals and other organisms
- ☐ ☐ Clinical data
- ☐ ☐ Dual use research of concern
- ☐ ☐ Plants

## Methods

- n/a Involved in the study
- ☐ ☐ ChIP-seq
- ☐ ☐ Flow cytometry
- ☐ ☐ MRI-based neuroimaging

## Antibodies

Antibodies used

Describe all antibodies used in the study; as applicable, provide supplier name, catalog number, clone name, and lot number.

Validation

Describe the validation of each primary antibody for the species and application, noting any validation statements on the manufacturer's website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.

## Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

State the source of each cell line used and the sex of all primary cell lines and cells derived from human participants or vertebrate models.

Authentication

Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.

Mycoplasma contamination

Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

Commonly misidentified lines  
(See [ICLAC](#) register)

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

## Palaeontology and Archaeology

Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information). Permits should encompass collection and, where applicable, export.

Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

☐ Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Animals and other research organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research, and [Sex and Gender in Research](#)

Laboratory animals

For laboratory animals, report species, strain and age OR state that the study did not involve laboratory animals.

Wild animals

Provide details on animals observed in or captured in the field; report species and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.

Reporting on sex

Indicate if findings apply to only one sex; describe whether sex was considered in study design, methods used for assigning sex. Provide data disaggregated for sex where this information has been collected in the source data as appropriate; provide overall

numbers in this Reporting Summary. Please state if this information has not been collected. Report sex-based analyses where performed, justify reasons for lack of sex-based analysis.

#### Field-collected samples

For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

#### Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

#### Clinical trial registration

Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

#### Study protocol

Note where the full trial protocol can be accessed OR if not available, explain why.

#### Data collection

Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

#### Outcomes

Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

## Dual use research of concern

Policy information about [dual use research of concern](#)

### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No	Yes
<input type="checkbox"/>	<input type="checkbox"/> Public health
<input type="checkbox"/>	<input type="checkbox"/> National security
<input type="checkbox"/>	<input type="checkbox"/> Crops and/or livestock
<input type="checkbox"/>	<input type="checkbox"/> Ecosystems
<input type="checkbox"/>	<input type="checkbox"/> Any other significant area

### Experiments of concern

Does the work involve any of these experiments of concern:

No	Yes
<input type="checkbox"/>	<input type="checkbox"/> Demonstrate how to render a vaccine ineffective
<input type="checkbox"/>	<input type="checkbox"/> Confer resistance to therapeutically useful antibiotics or antiviral agents
<input type="checkbox"/>	<input type="checkbox"/> Enhance the virulence of a pathogen or render a nonpathogen virulent
<input type="checkbox"/>	<input type="checkbox"/> Increase transmissibility of a pathogen
<input type="checkbox"/>	<input type="checkbox"/> Alter the host range of a pathogen
<input type="checkbox"/>	<input type="checkbox"/> Enable evasion of diagnostic/detection modalities
<input type="checkbox"/>	<input type="checkbox"/> Enable the weaponization of a biological agent or toxin
<input type="checkbox"/>	<input type="checkbox"/> Any other potentially harmful combination of experiments and agents

## Plants

Seed stocks	Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.
Novel plant genotypes	Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.
Authentication	Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosaicism, off-target gene editing) were examined.

## ChIP-seq

### Data deposition

- ☐ Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- ☐ Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links <i>May remain private before publication.</i>	For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.
Files in database submission	Provide a list of all files available in the database submission.
Genome browser session (e.g. <a href="#">UCSC</a> )	Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

### Methodology

Replicates	Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth	Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.
Antibodies	Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
Peak calling parameters	Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Data quality	Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
Software	Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

## Flow Cytometry

### Plots

Confirm that:

- ☐ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☐ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☐ All plots are contour plots with outliers or pseudocolor plots.
- ☐ A numerical value for number of cells or percentage (with statistics) is provided.

### Methodology

Sample preparation	Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.
Instrument	Identify the instrument used for data collection, specifying make and model number.
Software	Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.



Cell population abundance

Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.

Gating strategy

Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.

☐ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

### Experimental design

Design type

Indicate task or resting state; event-related or block design.

Design specifications

Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

Behavioral performance measures

State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

### Acquisition

Imaging type(s)

Specify: functional, structural, diffusion, perfusion.

Field strength

Specify in Tesla

Sequence &amp; imaging parameters

Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.

Area of acquisition

State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.

Diffusion MRI

☐ Used

☐ Not used

### Preprocessing

Preprocessing software

Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).

Normalization

If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.

Normalization template

Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.

Noise and artifact removal

Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).

Volume censoring

Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

### Statistical modeling & inference

Model type and settings

Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).

Effect(s) tested

Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.

Specify type of analysis: ☐ Whole brain ☐ ROI-based ☐ Both

Statistic type for inference

Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.

(See [Eklund et al. 2016](#))

Correction

Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).

Models & analysis

n/a	Involvement in the study	
<input type="checkbox"/>	<input type="checkbox"/> Functional and/or effective connectivity	
<input type="checkbox"/>	<input type="checkbox"/> Graph analysis	
<input type="checkbox"/>	<input type="checkbox"/> Multivariate modeling or predictive analysis	
Functional and/or effective connectivity		Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).
Graph analysis		Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).
Multivariate modeling and predictive analysis		Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.